California 2021-2022 Regular Session

California Assembly Bill AB593 Compare Versions

OldNewDifferences
1-Amended IN Assembly April 20, 2021 CALIFORNIA LEGISLATURE 20212022 REGULAR SESSION Assembly Bill No. 593Introduced by Assembly Members Petrie-Norris, Daly, Irwin, and Mullin(Principal coauthor: Assembly Member Cooper)(Principal coauthor: Senator Pan)(Coauthors: Assembly Members Aguiar-Curry, Bauer-Kahan, Berman, Choi, Cunningham, Davies, Frazier, Gray, Grayson, Levine, Low, Maienschein, and Waldron Mayes, Patterson, Luz Rivas, Salas, Seyarto, Valladares, Villapudua, Voepel, Waldron, and Ward)(Coauthors: Senators Dodd and Min Bates, Dodd, Min, and Wilk)February 11, 2021 An act to amend Sections 17039.3, 17276.23, and 23036.3 of the Revenue and Taxation Code, relating to taxation, to take effect immediately, tax levy. LEGISLATIVE COUNSEL'S DIGESTAB 593, as amended, Petrie-Norris. Income taxes: net operating losses: tax credits: research, development, and testing for diseases.Existing law, the Personal Income Tax Law and Corporation Tax Law, in modified conformity with federal income tax laws, generally allow various deductions in computing the income that is subject to taxes imposed by those laws, including a deduction for a net operating loss as specified. Existing law suspends the deduction for a net operating loss, as specified, for taxable years beginning on or after January 1, 2020, and before January 1, 2023.The Personal Income Tax Law and Corporation Tax Law generally authorize various credits against the taxes imposed by those laws. Existing law provides that, except as specified, the total credits allowable under those laws may not reduce the taxes imposed by those laws by more than $5,000,000, as provided, for taxable years beginning on or after January 1, 2020, and before January 1, 2023.This bill, the Golden State Innovation Act of 2021, would, for taxable years beginning on or after January 1, 2021, and before January 1, 2023, exclude a taxpayer that performs clinical, biomedical, or other research, development, or testing needed for COVID-19 or other diseases research and development in biotechnology, as described, from the above-described suspension of the deduction for net operating losses and the above-described limitation on the total credits allowable.Existing law requires any bill authorizing a new tax expenditure to contain, among other things, specific goals, purposes, and objectives that the tax expenditure will achieve, detailed performance indicators, and data collection requirements.The bill also would include additional information required for any bill authorizing a new tax expenditure.This bill would take effect immediately as a tax levy.Digest Key Vote: MAJORITY Appropriation: NO Fiscal Committee: YES Local Program: NO Bill TextThe people of the State of California do enact as follows:SECTION 1. This act shall be known, and may be cited as, the Golden State Innovation Act of 2021.SEC. 2. Section 17039.3 of the Revenue and Taxation Code is amended to read:17039.3. (a) Notwithstanding any provision of this part or Part 10.2 (commencing with Section 18401) to the contrary, for taxpayers not required to be included in a combined report under Section 25101 or 25110, or taxpayers not authorized to be included in a combined report under Section 25101.15, for each taxable year beginning on or after January 1, 2020, and before January 1, 2023, the total of all business credits otherwise allowable under any provision of Chapter 2 (commencing with Section 17041), including the carryover of any business credit under a former provision of that chapter, for the taxable year shall not reduce the net tax, as defined in Section 17039, by more than five million dollars ($5,000,000).(b) Notwithstanding any provision of this part or Part 10.2 (commencing with Section 18401) to the contrary, for taxpayers required to be included in a combined report under Section 25101 or 25110, or taxpayers authorized to be included in a combined report under Section 25101.15, for each taxable year beginning on or after January 1, 2020, and before January 1, 2023, the total of all business credits otherwise allowable under any provision of Chapter 2 (commencing with Section 17041), including the carryover of any business credit under a former provision of that chapter, by all members of the combined report shall not reduce the aggregate amount of tax, as defined in Section 23036, of all members of the combined report by more than five million dollars ($5,000,000).(c) For purposes of this section, business credit means a credit allowable under any provision of Chapter 2 (commencing with Section 17041) other than the following credits:(1) The credit allowed by Section 17052 (relating to credit for earned income).(2) The credit allowed by Section 17052.1 (relating to credit for young child).(3) The credit allowed by Section 17052.6 (relating to credit for household and dependent care).(4) The credit allowed by Section 17052.25 (relating to credit for adoption costs).(5) The credit allowed by Section 17053.5 (relating to renters tax credit).(6) The credit allowed by Section 17054 (relating to credit for personal exemption).(7) The credit allowed by Section 17054.5 (relating to credit for qualified joint custody head of household and a qualified taxpayer with a dependent parent).(8) The credit allowed by Section 17054.7 (relating to credit for qualified senior head of household).(9) The credit allowed by Section 17058 (relating to credit for low-income housing).(10) The credit allowed by Section 17061 (relating to refunds pursuant to the Unemployment Insurance Code).(d) Any amounts included in an election pursuant to Section 6902.5, relating to an irrevocable election to apply credit amounts under Section 17053.85, 17053.95, 17053.98, 23685, 23695, or 23698 against qualified sales and use tax, as defined in Section 6902.5, are not included in the five-million-dollar ($5,000,000) limitation set forth in subdivision (a) or (b).(e) The amount of any credit otherwise allowable for the taxable year under Section 17039 that is not allowed due to application of this section shall remain a credit carryover amount under this part.(f) The carryover period for any credit that is not allowed due to the application of this section shall be increased by the number of taxable years the credit or any portion thereof was not allowed.(g) Notwithstanding anything to the contrary in this part or Part 10.2 (commencing with Section 18401), the credits listed in subdivision (c) shall be applied after any business credits, as limited by subdivision (a) or (b), are applied.(h) Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code does not apply to any standard, criterion, procedure, determination, rule, notice, or guideline established or issued by the Franchise Tax Board pursuant to this section.(i) For taxable years beginning on or after January 1, 2021, and before January 2, 1, 2023, the five-million-dollar ($5,000,000) limitation set forth in subdivision (a) or (b) shall not apply to taxpayers that perform clinical, biomedical, or other research, development, or testing needed for COVID-19 or other diseases. research and development in biotechnology. A taxpayer performs research and development in biotechnology if the taxpayer is described in Code 325414 or 541714 of the 2017 edition of the North American Industry Classification System (NAICS) published by the United States Office of Management and Budget.SEC. 3. Section 17276.23 of the Revenue and Taxation Code is amended to read:17276.23. (a) Notwithstanding Sections 17276, 17276.1, 17276.4, 17276.7, and 17276.22, former Sections 17276.2, 17276.5, 17276.6, and 17276.20, and Section 172 of the Internal Revenue Code, a net operating loss deduction shall not be allowed for any taxable year beginning on or after January 1, 2020, and before January 1, 2023.(b) For any net operating loss or carryover of a net operating loss for which a deduction is denied by subdivision (a), the carryover period under Section 172 of the Internal Revenue Code shall be extended as follows:(1) By one year, for losses incurred in taxable years beginning on or after January 1, 2021, and before January 1, 2022.(2) By two years, for losses incurred in taxable years beginning on or after January 1, 2020, and before January 1, 2021.(3) By three years, for losses incurred in taxable years beginning before January 1, 2020.(c) This section shall not apply as follows:(1) For a taxable year beginning on or after January 1, 2020, and before January 1, 2023, this section shall not apply to a taxpayer with a net business income of less than one million dollars ($1,000,000) for the taxable year.(2) For a taxable year beginning on or after January 1, 2020, and before January 1, 2023, this section shall not apply to a taxpayer with a modified adjusted gross income of less than one million dollars ($1,000,000) for the taxable year.(3) For a taxable years year beginning on or after January 1, 2021, and before January 1, 2023, this section shall not apply to a taxpayer that perform clinical, biomedical, and other research, development, and testing needed for COVID-19 or other diseases. performs research and development in biotechnology. A taxpayer performs research and development in biotechnology if the taxpayer is described in Code 325414 or 541714 of the 2017 edition of the North American Industry Classification System (NAICS) published by the United States Office of Management and Budget.(d) For purposes of this section:(1) Business income means any of the following:(A) Income from a trade or business, whether conducted by the taxpayer or by a passthrough entity owned directly or indirectly by the taxpayer.(B) Income from rental activity.(C) Income attributable to a farming business.(2) Modified adjusted gross income means the amount described in paragraph (2) of subdivision (h) of Section 17024.5, determined without regard to the deduction allowed under Section 172 of the Internal Revenue Code, relating to net operating loss deduction.(3) Passthrough entity means a partnership or an S S corporation.SEC. 4. Section 23036.3 of the Revenue and Taxation Code is amended to read:23036.3. (a) Notwithstanding any provision of this part or Part 10.2 (commencing with Section 18401) to the contrary, except as provided in subdivision (d), for taxpayers not required to be included in a combined report under Section 25101 or 25110, or taxpayers not authorized to be included in a combined report under Section 25101.15, for each taxable year beginning on or after January 1, 2020, and before January 1, 2023, the total of all credits otherwise allowable under any provision of Chapter 3.5 (commencing with Section 23604) including the carryover of any credit under a former provision of that chapter, for the taxable year shall not reduce the tax, as defined in Section 23036, by more than five million dollars ($5,000,000).(b) Notwithstanding any provision of this part or Part 10.2 (commencing with Section 18401) to the contrary, except as provided in subdivision (d), for taxpayers required to be included in a combined report under Section 25101 or 25110, or taxpayers authorized to be included in a combined report under Section 25101.15, for each taxable year beginning on or after January 1, 2020, and before January 1, 2023, the total of all credits otherwise allowable under any provision of Chapter 3.5 (commencing with Section 23604), including the carryover of any credit under a former provision of that chapter, by all members of the combined report shall not reduce the aggregate amount of tax, as defined in Section 23036, of all members of the combined report by more than five-million-dollars five million dollars ($5,000,000).(c) Any amounts included in an election pursuant to Section 6902.5, relating to an irrevocable election to apply credit amounts under Section 17053.85, 17053.95, 17053.98, 23685, 23695, or 23698 against qualified sales and use tax, as defined in Section 6902.5, are not included in the five million dollar five-million-dollar ($5,000,000) limitation set forth in subdivision (a) or (b).(d) The limitation under subdivision (a) or (b) shall not apply to the credit allowed by Section 23610.5 (relating to credit for low-income housing).(e) The amount of any credit otherwise allowable for the taxable year under Section 23036 that is not allowed due to the application of this section shall remain a credit carryover amount under this part.(f) The carryover period for any credit that is not allowed due to the application of this section shall be increased by the number of taxable years the credit or any portion thereof was not allowed.(g) Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code does not apply to any standard, criterion, procedure, determination, rule, notice, or guideline established or issued by the Franchise Tax Board pursuant to this section.(h) For taxable years on or after January 1, 2021, and before January 2, 2023, the five-million-dollar ($5,000,000) limitation set forth in subdivision (a) or (b) shall not apply to taxpayers that perform clinical, biomedical, or other research, development, or testing needed for COVID-19 or other diseases. research and development in biotechnology. A taxpayer performs research and development in biotechnology if the taxpayer is described in Code 325414 or 541714 of the 2017 edition of the North American Industry Classification System (NAICS) published by the United States Office of Management and Budget.SEC. 5. (a) For purposes of Section 41 of the Revenue and Taxation Code, with respect to the tax expenditure created by the amendments to Sections 17039.3, 17276.23, and 23036.3 of the Revenue and Taxation Code made by this act, the Legislature finds and declares the following:(1) The specific goals, purposes, and objectives of this bill are as follows:(A) To encourage the activity of life sciences research in California.(B) To incentivize more research into treatments, cures, and vaccines to address the global pandemic caused by COVID-19.(2) To measure whether the credit achieves its intended purpose, the Franchise Tax Board shall prepare a written report on all of the following:(A) The number of taxpayers claiming the credit.(B) The average credit amount on tax returns claiming the credit.(C) Where applicable the type of taxpayer claiming the credit.(b) Notwithstanding Section 19542 of the Revenue and Taxation Code, the Franchise Tax Board shall provide the written report prepared pursuant to paragraph (2) of subdivision (a) to the Senate Committee on Budget and Fiscal Review, the Assembly Committee on Budget, the Senate and Assembly Committees on Appropriations, the Senate Committee on Governance and Finance, and the Assembly Committee on Revenue and Taxation. The report shall be submitted in compliance with Section 9795 of the Government Code.SEC. 6. This act provides for a tax levy within the meaning of Article IV of the California Constitution and shall go into immediate effect.
1+CALIFORNIA LEGISLATURE 20212022 REGULAR SESSION Assembly Bill No. 593Introduced by Assembly Members Petrie-Norris, Daly, Irwin, and Mullin(Principal coauthor: Senator Pan)(Coauthors: Assembly Members Low, Maienschein, and Waldron)(Coauthors: Senators Dodd and Min)February 11, 2021 An act to amend Sections 17039.3, 17276.23, and 23036.3 of the Revenue and Taxation Code, relating to taxation, to take effect immediately, tax levy. LEGISLATIVE COUNSEL'S DIGESTAB 593, as introduced, Petrie-Norris. Income taxes: net operating losses: tax credits: research, development, and testing for diseases.Existing law, the Personal Income Tax Law and Corporation Tax Law, in modified conformity with federal income tax laws, generally allow various deductions in computing the income that is subject to taxes imposed by those laws, including a deduction for a net operating loss as specified. Existing law suspends the deduction for a net operating loss, as specified, for taxable years beginning on or after January 1, 2020, and before January 1, 2023.The Personal Income Tax Law and Corporation Tax Law generally authorize various credits against the taxes imposed by those laws. Existing law provides that, except as specified, the total credits allowable under those laws may not reduce the taxes imposed by those laws by more than $5,000,000, as provided, for taxable years beginning on or after January 1, 2020, and before January 1, 2023.This bill, the Golden State Innovation Act of 2021, would, for taxable years beginning on or after January 1, 2021, and before January 1, 2023, exclude a taxpayer that performs clinical, biomedical, or other research, development, or testing needed for COVID-19 or other diseases from the above-described suspension of the deduction for net operating losses and the above-described limitation on the total credits allowable.Existing law requires any bill authorizing a new tax expenditure to contain, among other things, specific goals, purposes, and objectives that the tax expenditure will achieve, detailed performance indicators, and data collection requirements.The bill also would include additional information required for any bill authorizing a new tax expenditure.This bill would take effect immediately as a tax levy.Digest Key Vote: MAJORITY Appropriation: NO Fiscal Committee: YES Local Program: NO Bill TextThe people of the State of California do enact as follows:SECTION 1. This act shall be known, and may be cited as, the Golden State Innovation Act of 2021.SEC. 2. Section 17039.3 of the Revenue and Taxation Code is amended to read:17039.3. (a) Notwithstanding any provision of this part or Part 10.2 (commencing with Section 18401) to the contrary, for taxpayers not required to be included in a combined report under Section 25101 or 25110, or taxpayers not authorized to be included in a combined report under Section 25101.15, for each taxable year beginning on or after January 1, 2020, and before January 1, 2023, the total of all business credits otherwise allowable under any provision of Chapter 2 (commencing with Section 17041), including the carryover of any business credit under a former provision of that chapter, for the taxable year shall not reduce the net tax, as defined in Section 17039, by more than five million dollars ($5,000,000).(b) Notwithstanding any provision of this part or Part 10.2 (commencing with Section 18401) to the contrary, for taxpayers required to be included in a combined report under Section 25101 or 25110, or taxpayers authorized to be included in a combined report under Section 25101.15, for each taxable year beginning on or after January 1, 2020, and before January 1, 2023, the total of all business credits otherwise allowable under any provision of Chapter 2 (commencing with Section 17041), including the carryover of any business credit under a former provision of that chapter, by all members of the combined report shall not reduce the aggregate amount of tax, as defined in Section 23036, of all members of the combined report by more than five million dollars ($5,000,000).(c) For purposes of this section, business credit means a credit allowable under any provision of Chapter 2 (commencing with Section 17041) other than the following credits:(1) The credit allowed by Section 17052 (relating to credit for earned income).(2) The credit allowed by Section 17052.1 (relating to credit for young child).(3) The credit allowed by Section 17052.6 (relating to credit for household and dependent care).(4) The credit allowed by Section 17052.25 (relating to credit for adoption costs).(5) The credit allowed by Section 17053.5 (relating to renters tax credit).(6) The credit allowed by Section 17054 (relating to credit for personal exemption).(7) The credit allowed by Section 17054.5 (relating to credit for qualified joint custody head of household and a qualified taxpayer with a dependent parent).(8) The credit allowed by Section 17054.7 (relating to credit for qualified senior head of household).(9) The credit allowed by Section 17058 (relating to credit for low-income housing).(10) The credit allowed by Section 17061 (relating to refunds pursuant to the Unemployment Insurance Code).(d) Any amounts included in an election pursuant to Section 6902.5, relating to an irrevocable election to apply credit amounts under Section 17053.85, 17053.95, 17053.98, 23685, 23695, or 23698 against qualified sales and use tax, as defined in Section 6902.5, are not included in the five-million-dollar ($5,000,000) limitation set forth in subdivision (a) or (b).(e) The amount of any credit otherwise allowable for the taxable year under Section 17039 that is not allowed due to application of this section shall remain a credit carryover amount under this part.(f) The carryover period for any credit that is not allowed due to the application of this section shall be increased by the number of taxable years the credit or any portion thereof was not allowed.(g) Notwithstanding anything to the contrary in this part or Part 10.2 (commencing with Section 18401), the credits listed in subdivision (c) shall be applied after any business credits, as limited by subdivision (a) or (b), are applied.(h) Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code does not apply to any standard, criterion, procedure, determination, rule, notice, or guideline established or issued by the Franchise Tax Board pursuant to this section.(i) For taxable years on or after January 1, 2021, and before January 2, 2023, the five-million-dollar ($5,000,000) limitation set forth in subdivision (a) or (b) shall not apply to taxpayers that perform clinical, biomedical, or other research, development, or testing needed for COVID-19 or other diseases.SEC. 3. Section 17276.23 of the Revenue and Taxation Code is amended to read:17276.23. (a) Notwithstanding Sections 17276, 17276.1, 17276.4, 17276.7, and 17276.22, former Sections 17276.2, 17276.5, 17276.6, and 17276.20, and Section 172 of the Internal Revenue Code, a net operating loss deduction shall not be allowed for any taxable year beginning on or after January 1, 2020, and before January 1, 2023.(b) For any net operating loss or carryover of a net operating loss for which a deduction is denied by subdivision (a), the carryover period under Section 172 of the Internal Revenue Code shall be extended as follows:(1) By one year, for losses incurred in taxable years beginning on or after January 1, 2021, and before January 1, 2022.(2) By two years, for losses incurred in taxable years beginning on or after January 1, 2020, and before January 1, 2021.(3) By three years, for losses incurred in taxable years beginning before January 1, 2020.(c) This section shall not apply as follows:(1) For a taxable year beginning on or after January 1, 2020, and before January 1, 2023, this section shall not apply to a taxpayer with a net business income of less than one million dollars ($1,000,000) for the taxable year.(2) For a taxable year beginning on or after January 1, 2020, and before January 1, 2023, this section shall not apply to a taxpayer with a modified adjusted gross income of less than one million dollars ($1,000,000) for the taxable year.(3) For a taxable years beginning on or after January 1, 2021, and before January 1, 2023, this section shall not apply to a taxpayer that perform clinical, biomedical, and other research, development, and testing needed for COVID-19 or other diseases.(d) For purposes of this section:(1) Business income means any of the following:(A) Income from a trade or business, whether conducted by the taxpayer or by a passthrough entity owned directly or indirectly by the taxpayer.(B) Income from rental activity.(C) Income attributable to a farming business.(2) Modified adjusted gross income means the amount described in paragraph (2) of subdivision (h) of Section 17024.5, determined without regard to the deduction allowed under Section 172 of the Internal Revenue Code, relating to net operating loss deduction.(3) Passthrough entity means a partnership or an S corporation.SEC. 4. Section 23036.3 of the Revenue and Taxation Code is amended to read:23036.3. (a) Notwithstanding any provision of this part or Part 10.2 (commencing with Section 18401) to the contrary, except as provided in subdivision (d), for taxpayers not required to be included in a combined report under Section 25101 or 25110, or taxpayers not authorized to be included in a combined report under Section 25101.15, for each taxable year beginning on or after January 1, 2020, and before January 1, 2023, the total of all credits otherwise allowable under any provision of Chapter 3.5 (commencing with Section 23604) including the carryover of any credit under a former provision of that chapter, for the taxable year shall not reduce the tax, as defined in Section 23036, by more than five million dollars ($5,000,000).(b) Notwithstanding any provision of this part or Part 10.2 (commencing with Section 18401) to the contrary, except as provided in subdivision (d), for taxpayers required to be included in a combined report under Section 25101 or 25110, or taxpayers authorized to be included in a combined report under Section 25101.15, for each taxable year beginning on or after January 1, 2020, and before January 1, 2023, the total of all credits otherwise allowable under any provision of Chapter 3.5 (commencing with Section 23604), including the carryover of any credit under a former provision of that chapter, by all members of the combined report shall not reduce the aggregate amount of tax, as defined in Section 23036, of all members of the combined report by more than five-million-dollars ($5,000,000).(c) Any amounts included in an election pursuant to Section 6902.5, relating to an irrevocable election to apply credit amounts under Section 17053.85, 17053.95, 17053.98, 23685, 23695, or 23698 against qualified sales and use tax, as defined in Section 6902.5, are not included in the five million dollar ($5,000,000) limitation set forth in subdivision (a) or (b).(d) The limitation under subdivision (a) or (b) shall not apply to the credit allowed by Section 23610.5 (relating to credit for low-income housing).(e) The amount of any credit otherwise allowable for the taxable year under Section 23036 that is not allowed due to the application of this section shall remain a credit carryover amount under this part.(f) The carryover period for any credit that is not allowed due to the application of this section shall be increased by the number of taxable years the credit or any portion thereof was not allowed.(g) Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code does not apply to any standard, criterion, procedure, determination, rule, notice, or guideline established or issued by the Franchise Tax Board pursuant to this section.(h) For taxable years on or after January 1, 2021, and before January 2, 2023, the five-million-dollar ($5,000,000) limitation set forth in subdivision (a) or (b) shall not apply to taxpayers that perform clinical, biomedical, or other research, development, or testing needed for COVID-19 or other diseases.SEC. 5. (a) For purposes of Section 41 of the Revenue and Taxation Code, with respect to the tax expenditure created by the amendments to Sections 17039.3, 17276.23, and 23036.3 of the Revenue and Taxation Code made by this act, the Legislature finds and declares the following:(1) The specific goals, purposes, and objectives of this bill are as follows:(A) To encourage the activity of life sciences research in California.(B) To incentivize more research into treatments, cures, and vaccines to address the global pandemic caused by COVID-19.(2) To measure whether the credit achieves its intended purpose, the Franchise Tax Board shall prepare a written report on all of the following:(A) The number of taxpayers claiming the credit.(B) The average credit amount on tax returns claiming the credit.(C) Where applicable the type of taxpayer claiming the credit.(b) Notwithstanding Section 19542 of the Revenue and Taxation Code, the Franchise Tax Board shall provide the written report prepared pursuant to paragraph (2) of subdivision (a) to the Senate Committee on Budget and Fiscal Review, the Assembly Committee on Budget, the Senate and Assembly Committees on Appropriations, the Senate Committee on Governance and Finance, and the Assembly Committee on Revenue and Taxation. The report shall be submitted in compliance with Section 9795 of the Government Code.SEC. 6. This act provides for a tax levy within the meaning of Article IV of the California Constitution and shall go into immediate effect.
22
3- Amended IN Assembly April 20, 2021 CALIFORNIA LEGISLATURE 20212022 REGULAR SESSION Assembly Bill No. 593Introduced by Assembly Members Petrie-Norris, Daly, Irwin, and Mullin(Principal coauthor: Assembly Member Cooper)(Principal coauthor: Senator Pan)(Coauthors: Assembly Members Aguiar-Curry, Bauer-Kahan, Berman, Choi, Cunningham, Davies, Frazier, Gray, Grayson, Levine, Low, Maienschein, and Waldron Mayes, Patterson, Luz Rivas, Salas, Seyarto, Valladares, Villapudua, Voepel, Waldron, and Ward)(Coauthors: Senators Dodd and Min Bates, Dodd, Min, and Wilk)February 11, 2021 An act to amend Sections 17039.3, 17276.23, and 23036.3 of the Revenue and Taxation Code, relating to taxation, to take effect immediately, tax levy. LEGISLATIVE COUNSEL'S DIGESTAB 593, as amended, Petrie-Norris. Income taxes: net operating losses: tax credits: research, development, and testing for diseases.Existing law, the Personal Income Tax Law and Corporation Tax Law, in modified conformity with federal income tax laws, generally allow various deductions in computing the income that is subject to taxes imposed by those laws, including a deduction for a net operating loss as specified. Existing law suspends the deduction for a net operating loss, as specified, for taxable years beginning on or after January 1, 2020, and before January 1, 2023.The Personal Income Tax Law and Corporation Tax Law generally authorize various credits against the taxes imposed by those laws. Existing law provides that, except as specified, the total credits allowable under those laws may not reduce the taxes imposed by those laws by more than $5,000,000, as provided, for taxable years beginning on or after January 1, 2020, and before January 1, 2023.This bill, the Golden State Innovation Act of 2021, would, for taxable years beginning on or after January 1, 2021, and before January 1, 2023, exclude a taxpayer that performs clinical, biomedical, or other research, development, or testing needed for COVID-19 or other diseases research and development in biotechnology, as described, from the above-described suspension of the deduction for net operating losses and the above-described limitation on the total credits allowable.Existing law requires any bill authorizing a new tax expenditure to contain, among other things, specific goals, purposes, and objectives that the tax expenditure will achieve, detailed performance indicators, and data collection requirements.The bill also would include additional information required for any bill authorizing a new tax expenditure.This bill would take effect immediately as a tax levy.Digest Key Vote: MAJORITY Appropriation: NO Fiscal Committee: YES Local Program: NO
3+ CALIFORNIA LEGISLATURE 20212022 REGULAR SESSION Assembly Bill No. 593Introduced by Assembly Members Petrie-Norris, Daly, Irwin, and Mullin(Principal coauthor: Senator Pan)(Coauthors: Assembly Members Low, Maienschein, and Waldron)(Coauthors: Senators Dodd and Min)February 11, 2021 An act to amend Sections 17039.3, 17276.23, and 23036.3 of the Revenue and Taxation Code, relating to taxation, to take effect immediately, tax levy. LEGISLATIVE COUNSEL'S DIGESTAB 593, as introduced, Petrie-Norris. Income taxes: net operating losses: tax credits: research, development, and testing for diseases.Existing law, the Personal Income Tax Law and Corporation Tax Law, in modified conformity with federal income tax laws, generally allow various deductions in computing the income that is subject to taxes imposed by those laws, including a deduction for a net operating loss as specified. Existing law suspends the deduction for a net operating loss, as specified, for taxable years beginning on or after January 1, 2020, and before January 1, 2023.The Personal Income Tax Law and Corporation Tax Law generally authorize various credits against the taxes imposed by those laws. Existing law provides that, except as specified, the total credits allowable under those laws may not reduce the taxes imposed by those laws by more than $5,000,000, as provided, for taxable years beginning on or after January 1, 2020, and before January 1, 2023.This bill, the Golden State Innovation Act of 2021, would, for taxable years beginning on or after January 1, 2021, and before January 1, 2023, exclude a taxpayer that performs clinical, biomedical, or other research, development, or testing needed for COVID-19 or other diseases from the above-described suspension of the deduction for net operating losses and the above-described limitation on the total credits allowable.Existing law requires any bill authorizing a new tax expenditure to contain, among other things, specific goals, purposes, and objectives that the tax expenditure will achieve, detailed performance indicators, and data collection requirements.The bill also would include additional information required for any bill authorizing a new tax expenditure.This bill would take effect immediately as a tax levy.Digest Key Vote: MAJORITY Appropriation: NO Fiscal Committee: YES Local Program: NO
44
5- Amended IN Assembly April 20, 2021
65
7-Amended IN Assembly April 20, 2021
6+
7+
88
99 CALIFORNIA LEGISLATURE 20212022 REGULAR SESSION
1010
1111 Assembly Bill
1212
1313 No. 593
1414
15-Introduced by Assembly Members Petrie-Norris, Daly, Irwin, and Mullin(Principal coauthor: Assembly Member Cooper)(Principal coauthor: Senator Pan)(Coauthors: Assembly Members Aguiar-Curry, Bauer-Kahan, Berman, Choi, Cunningham, Davies, Frazier, Gray, Grayson, Levine, Low, Maienschein, and Waldron Mayes, Patterson, Luz Rivas, Salas, Seyarto, Valladares, Villapudua, Voepel, Waldron, and Ward)(Coauthors: Senators Dodd and Min Bates, Dodd, Min, and Wilk)February 11, 2021
15+Introduced by Assembly Members Petrie-Norris, Daly, Irwin, and Mullin(Principal coauthor: Senator Pan)(Coauthors: Assembly Members Low, Maienschein, and Waldron)(Coauthors: Senators Dodd and Min)February 11, 2021
1616
17-Introduced by Assembly Members Petrie-Norris, Daly, Irwin, and Mullin(Principal coauthor: Assembly Member Cooper)(Principal coauthor: Senator Pan)(Coauthors: Assembly Members Aguiar-Curry, Bauer-Kahan, Berman, Choi, Cunningham, Davies, Frazier, Gray, Grayson, Levine, Low, Maienschein, and Waldron Mayes, Patterson, Luz Rivas, Salas, Seyarto, Valladares, Villapudua, Voepel, Waldron, and Ward)(Coauthors: Senators Dodd and Min Bates, Dodd, Min, and Wilk)
17+Introduced by Assembly Members Petrie-Norris, Daly, Irwin, and Mullin(Principal coauthor: Senator Pan)(Coauthors: Assembly Members Low, Maienschein, and Waldron)(Coauthors: Senators Dodd and Min)
1818 February 11, 2021
1919
2020 An act to amend Sections 17039.3, 17276.23, and 23036.3 of the Revenue and Taxation Code, relating to taxation, to take effect immediately, tax levy.
2121
2222 LEGISLATIVE COUNSEL'S DIGEST
2323
2424 ## LEGISLATIVE COUNSEL'S DIGEST
2525
26-AB 593, as amended, Petrie-Norris. Income taxes: net operating losses: tax credits: research, development, and testing for diseases.
26+AB 593, as introduced, Petrie-Norris. Income taxes: net operating losses: tax credits: research, development, and testing for diseases.
2727
28-Existing law, the Personal Income Tax Law and Corporation Tax Law, in modified conformity with federal income tax laws, generally allow various deductions in computing the income that is subject to taxes imposed by those laws, including a deduction for a net operating loss as specified. Existing law suspends the deduction for a net operating loss, as specified, for taxable years beginning on or after January 1, 2020, and before January 1, 2023.The Personal Income Tax Law and Corporation Tax Law generally authorize various credits against the taxes imposed by those laws. Existing law provides that, except as specified, the total credits allowable under those laws may not reduce the taxes imposed by those laws by more than $5,000,000, as provided, for taxable years beginning on or after January 1, 2020, and before January 1, 2023.This bill, the Golden State Innovation Act of 2021, would, for taxable years beginning on or after January 1, 2021, and before January 1, 2023, exclude a taxpayer that performs clinical, biomedical, or other research, development, or testing needed for COVID-19 or other diseases research and development in biotechnology, as described, from the above-described suspension of the deduction for net operating losses and the above-described limitation on the total credits allowable.Existing law requires any bill authorizing a new tax expenditure to contain, among other things, specific goals, purposes, and objectives that the tax expenditure will achieve, detailed performance indicators, and data collection requirements.The bill also would include additional information required for any bill authorizing a new tax expenditure.This bill would take effect immediately as a tax levy.
28+Existing law, the Personal Income Tax Law and Corporation Tax Law, in modified conformity with federal income tax laws, generally allow various deductions in computing the income that is subject to taxes imposed by those laws, including a deduction for a net operating loss as specified. Existing law suspends the deduction for a net operating loss, as specified, for taxable years beginning on or after January 1, 2020, and before January 1, 2023.The Personal Income Tax Law and Corporation Tax Law generally authorize various credits against the taxes imposed by those laws. Existing law provides that, except as specified, the total credits allowable under those laws may not reduce the taxes imposed by those laws by more than $5,000,000, as provided, for taxable years beginning on or after January 1, 2020, and before January 1, 2023.This bill, the Golden State Innovation Act of 2021, would, for taxable years beginning on or after January 1, 2021, and before January 1, 2023, exclude a taxpayer that performs clinical, biomedical, or other research, development, or testing needed for COVID-19 or other diseases from the above-described suspension of the deduction for net operating losses and the above-described limitation on the total credits allowable.Existing law requires any bill authorizing a new tax expenditure to contain, among other things, specific goals, purposes, and objectives that the tax expenditure will achieve, detailed performance indicators, and data collection requirements.The bill also would include additional information required for any bill authorizing a new tax expenditure.This bill would take effect immediately as a tax levy.
2929
3030 Existing law, the Personal Income Tax Law and Corporation Tax Law, in modified conformity with federal income tax laws, generally allow various deductions in computing the income that is subject to taxes imposed by those laws, including a deduction for a net operating loss as specified. Existing law suspends the deduction for a net operating loss, as specified, for taxable years beginning on or after January 1, 2020, and before January 1, 2023.
3131
3232 The Personal Income Tax Law and Corporation Tax Law generally authorize various credits against the taxes imposed by those laws. Existing law provides that, except as specified, the total credits allowable under those laws may not reduce the taxes imposed by those laws by more than $5,000,000, as provided, for taxable years beginning on or after January 1, 2020, and before January 1, 2023.
3333
34-This bill, the Golden State Innovation Act of 2021, would, for taxable years beginning on or after January 1, 2021, and before January 1, 2023, exclude a taxpayer that performs clinical, biomedical, or other research, development, or testing needed for COVID-19 or other diseases research and development in biotechnology, as described, from the above-described suspension of the deduction for net operating losses and the above-described limitation on the total credits allowable.
34+This bill, the Golden State Innovation Act of 2021, would, for taxable years beginning on or after January 1, 2021, and before January 1, 2023, exclude a taxpayer that performs clinical, biomedical, or other research, development, or testing needed for COVID-19 or other diseases from the above-described suspension of the deduction for net operating losses and the above-described limitation on the total credits allowable.
3535
3636 Existing law requires any bill authorizing a new tax expenditure to contain, among other things, specific goals, purposes, and objectives that the tax expenditure will achieve, detailed performance indicators, and data collection requirements.
3737
3838 The bill also would include additional information required for any bill authorizing a new tax expenditure.
3939
4040 This bill would take effect immediately as a tax levy.
4141
4242 ## Digest Key
4343
4444 ## Bill Text
4545
46-The people of the State of California do enact as follows:SECTION 1. This act shall be known, and may be cited as, the Golden State Innovation Act of 2021.SEC. 2. Section 17039.3 of the Revenue and Taxation Code is amended to read:17039.3. (a) Notwithstanding any provision of this part or Part 10.2 (commencing with Section 18401) to the contrary, for taxpayers not required to be included in a combined report under Section 25101 or 25110, or taxpayers not authorized to be included in a combined report under Section 25101.15, for each taxable year beginning on or after January 1, 2020, and before January 1, 2023, the total of all business credits otherwise allowable under any provision of Chapter 2 (commencing with Section 17041), including the carryover of any business credit under a former provision of that chapter, for the taxable year shall not reduce the net tax, as defined in Section 17039, by more than five million dollars ($5,000,000).(b) Notwithstanding any provision of this part or Part 10.2 (commencing with Section 18401) to the contrary, for taxpayers required to be included in a combined report under Section 25101 or 25110, or taxpayers authorized to be included in a combined report under Section 25101.15, for each taxable year beginning on or after January 1, 2020, and before January 1, 2023, the total of all business credits otherwise allowable under any provision of Chapter 2 (commencing with Section 17041), including the carryover of any business credit under a former provision of that chapter, by all members of the combined report shall not reduce the aggregate amount of tax, as defined in Section 23036, of all members of the combined report by more than five million dollars ($5,000,000).(c) For purposes of this section, business credit means a credit allowable under any provision of Chapter 2 (commencing with Section 17041) other than the following credits:(1) The credit allowed by Section 17052 (relating to credit for earned income).(2) The credit allowed by Section 17052.1 (relating to credit for young child).(3) The credit allowed by Section 17052.6 (relating to credit for household and dependent care).(4) The credit allowed by Section 17052.25 (relating to credit for adoption costs).(5) The credit allowed by Section 17053.5 (relating to renters tax credit).(6) The credit allowed by Section 17054 (relating to credit for personal exemption).(7) The credit allowed by Section 17054.5 (relating to credit for qualified joint custody head of household and a qualified taxpayer with a dependent parent).(8) The credit allowed by Section 17054.7 (relating to credit for qualified senior head of household).(9) The credit allowed by Section 17058 (relating to credit for low-income housing).(10) The credit allowed by Section 17061 (relating to refunds pursuant to the Unemployment Insurance Code).(d) Any amounts included in an election pursuant to Section 6902.5, relating to an irrevocable election to apply credit amounts under Section 17053.85, 17053.95, 17053.98, 23685, 23695, or 23698 against qualified sales and use tax, as defined in Section 6902.5, are not included in the five-million-dollar ($5,000,000) limitation set forth in subdivision (a) or (b).(e) The amount of any credit otherwise allowable for the taxable year under Section 17039 that is not allowed due to application of this section shall remain a credit carryover amount under this part.(f) The carryover period for any credit that is not allowed due to the application of this section shall be increased by the number of taxable years the credit or any portion thereof was not allowed.(g) Notwithstanding anything to the contrary in this part or Part 10.2 (commencing with Section 18401), the credits listed in subdivision (c) shall be applied after any business credits, as limited by subdivision (a) or (b), are applied.(h) Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code does not apply to any standard, criterion, procedure, determination, rule, notice, or guideline established or issued by the Franchise Tax Board pursuant to this section.(i) For taxable years beginning on or after January 1, 2021, and before January 2, 1, 2023, the five-million-dollar ($5,000,000) limitation set forth in subdivision (a) or (b) shall not apply to taxpayers that perform clinical, biomedical, or other research, development, or testing needed for COVID-19 or other diseases. research and development in biotechnology. A taxpayer performs research and development in biotechnology if the taxpayer is described in Code 325414 or 541714 of the 2017 edition of the North American Industry Classification System (NAICS) published by the United States Office of Management and Budget.SEC. 3. Section 17276.23 of the Revenue and Taxation Code is amended to read:17276.23. (a) Notwithstanding Sections 17276, 17276.1, 17276.4, 17276.7, and 17276.22, former Sections 17276.2, 17276.5, 17276.6, and 17276.20, and Section 172 of the Internal Revenue Code, a net operating loss deduction shall not be allowed for any taxable year beginning on or after January 1, 2020, and before January 1, 2023.(b) For any net operating loss or carryover of a net operating loss for which a deduction is denied by subdivision (a), the carryover period under Section 172 of the Internal Revenue Code shall be extended as follows:(1) By one year, for losses incurred in taxable years beginning on or after January 1, 2021, and before January 1, 2022.(2) By two years, for losses incurred in taxable years beginning on or after January 1, 2020, and before January 1, 2021.(3) By three years, for losses incurred in taxable years beginning before January 1, 2020.(c) This section shall not apply as follows:(1) For a taxable year beginning on or after January 1, 2020, and before January 1, 2023, this section shall not apply to a taxpayer with a net business income of less than one million dollars ($1,000,000) for the taxable year.(2) For a taxable year beginning on or after January 1, 2020, and before January 1, 2023, this section shall not apply to a taxpayer with a modified adjusted gross income of less than one million dollars ($1,000,000) for the taxable year.(3) For a taxable years year beginning on or after January 1, 2021, and before January 1, 2023, this section shall not apply to a taxpayer that perform clinical, biomedical, and other research, development, and testing needed for COVID-19 or other diseases. performs research and development in biotechnology. A taxpayer performs research and development in biotechnology if the taxpayer is described in Code 325414 or 541714 of the 2017 edition of the North American Industry Classification System (NAICS) published by the United States Office of Management and Budget.(d) For purposes of this section:(1) Business income means any of the following:(A) Income from a trade or business, whether conducted by the taxpayer or by a passthrough entity owned directly or indirectly by the taxpayer.(B) Income from rental activity.(C) Income attributable to a farming business.(2) Modified adjusted gross income means the amount described in paragraph (2) of subdivision (h) of Section 17024.5, determined without regard to the deduction allowed under Section 172 of the Internal Revenue Code, relating to net operating loss deduction.(3) Passthrough entity means a partnership or an S S corporation.SEC. 4. Section 23036.3 of the Revenue and Taxation Code is amended to read:23036.3. (a) Notwithstanding any provision of this part or Part 10.2 (commencing with Section 18401) to the contrary, except as provided in subdivision (d), for taxpayers not required to be included in a combined report under Section 25101 or 25110, or taxpayers not authorized to be included in a combined report under Section 25101.15, for each taxable year beginning on or after January 1, 2020, and before January 1, 2023, the total of all credits otherwise allowable under any provision of Chapter 3.5 (commencing with Section 23604) including the carryover of any credit under a former provision of that chapter, for the taxable year shall not reduce the tax, as defined in Section 23036, by more than five million dollars ($5,000,000).(b) Notwithstanding any provision of this part or Part 10.2 (commencing with Section 18401) to the contrary, except as provided in subdivision (d), for taxpayers required to be included in a combined report under Section 25101 or 25110, or taxpayers authorized to be included in a combined report under Section 25101.15, for each taxable year beginning on or after January 1, 2020, and before January 1, 2023, the total of all credits otherwise allowable under any provision of Chapter 3.5 (commencing with Section 23604), including the carryover of any credit under a former provision of that chapter, by all members of the combined report shall not reduce the aggregate amount of tax, as defined in Section 23036, of all members of the combined report by more than five-million-dollars five million dollars ($5,000,000).(c) Any amounts included in an election pursuant to Section 6902.5, relating to an irrevocable election to apply credit amounts under Section 17053.85, 17053.95, 17053.98, 23685, 23695, or 23698 against qualified sales and use tax, as defined in Section 6902.5, are not included in the five million dollar five-million-dollar ($5,000,000) limitation set forth in subdivision (a) or (b).(d) The limitation under subdivision (a) or (b) shall not apply to the credit allowed by Section 23610.5 (relating to credit for low-income housing).(e) The amount of any credit otherwise allowable for the taxable year under Section 23036 that is not allowed due to the application of this section shall remain a credit carryover amount under this part.(f) The carryover period for any credit that is not allowed due to the application of this section shall be increased by the number of taxable years the credit or any portion thereof was not allowed.(g) Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code does not apply to any standard, criterion, procedure, determination, rule, notice, or guideline established or issued by the Franchise Tax Board pursuant to this section.(h) For taxable years on or after January 1, 2021, and before January 2, 2023, the five-million-dollar ($5,000,000) limitation set forth in subdivision (a) or (b) shall not apply to taxpayers that perform clinical, biomedical, or other research, development, or testing needed for COVID-19 or other diseases. research and development in biotechnology. A taxpayer performs research and development in biotechnology if the taxpayer is described in Code 325414 or 541714 of the 2017 edition of the North American Industry Classification System (NAICS) published by the United States Office of Management and Budget.SEC. 5. (a) For purposes of Section 41 of the Revenue and Taxation Code, with respect to the tax expenditure created by the amendments to Sections 17039.3, 17276.23, and 23036.3 of the Revenue and Taxation Code made by this act, the Legislature finds and declares the following:(1) The specific goals, purposes, and objectives of this bill are as follows:(A) To encourage the activity of life sciences research in California.(B) To incentivize more research into treatments, cures, and vaccines to address the global pandemic caused by COVID-19.(2) To measure whether the credit achieves its intended purpose, the Franchise Tax Board shall prepare a written report on all of the following:(A) The number of taxpayers claiming the credit.(B) The average credit amount on tax returns claiming the credit.(C) Where applicable the type of taxpayer claiming the credit.(b) Notwithstanding Section 19542 of the Revenue and Taxation Code, the Franchise Tax Board shall provide the written report prepared pursuant to paragraph (2) of subdivision (a) to the Senate Committee on Budget and Fiscal Review, the Assembly Committee on Budget, the Senate and Assembly Committees on Appropriations, the Senate Committee on Governance and Finance, and the Assembly Committee on Revenue and Taxation. The report shall be submitted in compliance with Section 9795 of the Government Code.SEC. 6. This act provides for a tax levy within the meaning of Article IV of the California Constitution and shall go into immediate effect.
46+The people of the State of California do enact as follows:SECTION 1. This act shall be known, and may be cited as, the Golden State Innovation Act of 2021.SEC. 2. Section 17039.3 of the Revenue and Taxation Code is amended to read:17039.3. (a) Notwithstanding any provision of this part or Part 10.2 (commencing with Section 18401) to the contrary, for taxpayers not required to be included in a combined report under Section 25101 or 25110, or taxpayers not authorized to be included in a combined report under Section 25101.15, for each taxable year beginning on or after January 1, 2020, and before January 1, 2023, the total of all business credits otherwise allowable under any provision of Chapter 2 (commencing with Section 17041), including the carryover of any business credit under a former provision of that chapter, for the taxable year shall not reduce the net tax, as defined in Section 17039, by more than five million dollars ($5,000,000).(b) Notwithstanding any provision of this part or Part 10.2 (commencing with Section 18401) to the contrary, for taxpayers required to be included in a combined report under Section 25101 or 25110, or taxpayers authorized to be included in a combined report under Section 25101.15, for each taxable year beginning on or after January 1, 2020, and before January 1, 2023, the total of all business credits otherwise allowable under any provision of Chapter 2 (commencing with Section 17041), including the carryover of any business credit under a former provision of that chapter, by all members of the combined report shall not reduce the aggregate amount of tax, as defined in Section 23036, of all members of the combined report by more than five million dollars ($5,000,000).(c) For purposes of this section, business credit means a credit allowable under any provision of Chapter 2 (commencing with Section 17041) other than the following credits:(1) The credit allowed by Section 17052 (relating to credit for earned income).(2) The credit allowed by Section 17052.1 (relating to credit for young child).(3) The credit allowed by Section 17052.6 (relating to credit for household and dependent care).(4) The credit allowed by Section 17052.25 (relating to credit for adoption costs).(5) The credit allowed by Section 17053.5 (relating to renters tax credit).(6) The credit allowed by Section 17054 (relating to credit for personal exemption).(7) The credit allowed by Section 17054.5 (relating to credit for qualified joint custody head of household and a qualified taxpayer with a dependent parent).(8) The credit allowed by Section 17054.7 (relating to credit for qualified senior head of household).(9) The credit allowed by Section 17058 (relating to credit for low-income housing).(10) The credit allowed by Section 17061 (relating to refunds pursuant to the Unemployment Insurance Code).(d) Any amounts included in an election pursuant to Section 6902.5, relating to an irrevocable election to apply credit amounts under Section 17053.85, 17053.95, 17053.98, 23685, 23695, or 23698 against qualified sales and use tax, as defined in Section 6902.5, are not included in the five-million-dollar ($5,000,000) limitation set forth in subdivision (a) or (b).(e) The amount of any credit otherwise allowable for the taxable year under Section 17039 that is not allowed due to application of this section shall remain a credit carryover amount under this part.(f) The carryover period for any credit that is not allowed due to the application of this section shall be increased by the number of taxable years the credit or any portion thereof was not allowed.(g) Notwithstanding anything to the contrary in this part or Part 10.2 (commencing with Section 18401), the credits listed in subdivision (c) shall be applied after any business credits, as limited by subdivision (a) or (b), are applied.(h) Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code does not apply to any standard, criterion, procedure, determination, rule, notice, or guideline established or issued by the Franchise Tax Board pursuant to this section.(i) For taxable years on or after January 1, 2021, and before January 2, 2023, the five-million-dollar ($5,000,000) limitation set forth in subdivision (a) or (b) shall not apply to taxpayers that perform clinical, biomedical, or other research, development, or testing needed for COVID-19 or other diseases.SEC. 3. Section 17276.23 of the Revenue and Taxation Code is amended to read:17276.23. (a) Notwithstanding Sections 17276, 17276.1, 17276.4, 17276.7, and 17276.22, former Sections 17276.2, 17276.5, 17276.6, and 17276.20, and Section 172 of the Internal Revenue Code, a net operating loss deduction shall not be allowed for any taxable year beginning on or after January 1, 2020, and before January 1, 2023.(b) For any net operating loss or carryover of a net operating loss for which a deduction is denied by subdivision (a), the carryover period under Section 172 of the Internal Revenue Code shall be extended as follows:(1) By one year, for losses incurred in taxable years beginning on or after January 1, 2021, and before January 1, 2022.(2) By two years, for losses incurred in taxable years beginning on or after January 1, 2020, and before January 1, 2021.(3) By three years, for losses incurred in taxable years beginning before January 1, 2020.(c) This section shall not apply as follows:(1) For a taxable year beginning on or after January 1, 2020, and before January 1, 2023, this section shall not apply to a taxpayer with a net business income of less than one million dollars ($1,000,000) for the taxable year.(2) For a taxable year beginning on or after January 1, 2020, and before January 1, 2023, this section shall not apply to a taxpayer with a modified adjusted gross income of less than one million dollars ($1,000,000) for the taxable year.(3) For a taxable years beginning on or after January 1, 2021, and before January 1, 2023, this section shall not apply to a taxpayer that perform clinical, biomedical, and other research, development, and testing needed for COVID-19 or other diseases.(d) For purposes of this section:(1) Business income means any of the following:(A) Income from a trade or business, whether conducted by the taxpayer or by a passthrough entity owned directly or indirectly by the taxpayer.(B) Income from rental activity.(C) Income attributable to a farming business.(2) Modified adjusted gross income means the amount described in paragraph (2) of subdivision (h) of Section 17024.5, determined without regard to the deduction allowed under Section 172 of the Internal Revenue Code, relating to net operating loss deduction.(3) Passthrough entity means a partnership or an S corporation.SEC. 4. Section 23036.3 of the Revenue and Taxation Code is amended to read:23036.3. (a) Notwithstanding any provision of this part or Part 10.2 (commencing with Section 18401) to the contrary, except as provided in subdivision (d), for taxpayers not required to be included in a combined report under Section 25101 or 25110, or taxpayers not authorized to be included in a combined report under Section 25101.15, for each taxable year beginning on or after January 1, 2020, and before January 1, 2023, the total of all credits otherwise allowable under any provision of Chapter 3.5 (commencing with Section 23604) including the carryover of any credit under a former provision of that chapter, for the taxable year shall not reduce the tax, as defined in Section 23036, by more than five million dollars ($5,000,000).(b) Notwithstanding any provision of this part or Part 10.2 (commencing with Section 18401) to the contrary, except as provided in subdivision (d), for taxpayers required to be included in a combined report under Section 25101 or 25110, or taxpayers authorized to be included in a combined report under Section 25101.15, for each taxable year beginning on or after January 1, 2020, and before January 1, 2023, the total of all credits otherwise allowable under any provision of Chapter 3.5 (commencing with Section 23604), including the carryover of any credit under a former provision of that chapter, by all members of the combined report shall not reduce the aggregate amount of tax, as defined in Section 23036, of all members of the combined report by more than five-million-dollars ($5,000,000).(c) Any amounts included in an election pursuant to Section 6902.5, relating to an irrevocable election to apply credit amounts under Section 17053.85, 17053.95, 17053.98, 23685, 23695, or 23698 against qualified sales and use tax, as defined in Section 6902.5, are not included in the five million dollar ($5,000,000) limitation set forth in subdivision (a) or (b).(d) The limitation under subdivision (a) or (b) shall not apply to the credit allowed by Section 23610.5 (relating to credit for low-income housing).(e) The amount of any credit otherwise allowable for the taxable year under Section 23036 that is not allowed due to the application of this section shall remain a credit carryover amount under this part.(f) The carryover period for any credit that is not allowed due to the application of this section shall be increased by the number of taxable years the credit or any portion thereof was not allowed.(g) Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code does not apply to any standard, criterion, procedure, determination, rule, notice, or guideline established or issued by the Franchise Tax Board pursuant to this section.(h) For taxable years on or after January 1, 2021, and before January 2, 2023, the five-million-dollar ($5,000,000) limitation set forth in subdivision (a) or (b) shall not apply to taxpayers that perform clinical, biomedical, or other research, development, or testing needed for COVID-19 or other diseases.SEC. 5. (a) For purposes of Section 41 of the Revenue and Taxation Code, with respect to the tax expenditure created by the amendments to Sections 17039.3, 17276.23, and 23036.3 of the Revenue and Taxation Code made by this act, the Legislature finds and declares the following:(1) The specific goals, purposes, and objectives of this bill are as follows:(A) To encourage the activity of life sciences research in California.(B) To incentivize more research into treatments, cures, and vaccines to address the global pandemic caused by COVID-19.(2) To measure whether the credit achieves its intended purpose, the Franchise Tax Board shall prepare a written report on all of the following:(A) The number of taxpayers claiming the credit.(B) The average credit amount on tax returns claiming the credit.(C) Where applicable the type of taxpayer claiming the credit.(b) Notwithstanding Section 19542 of the Revenue and Taxation Code, the Franchise Tax Board shall provide the written report prepared pursuant to paragraph (2) of subdivision (a) to the Senate Committee on Budget and Fiscal Review, the Assembly Committee on Budget, the Senate and Assembly Committees on Appropriations, the Senate Committee on Governance and Finance, and the Assembly Committee on Revenue and Taxation. The report shall be submitted in compliance with Section 9795 of the Government Code.SEC. 6. This act provides for a tax levy within the meaning of Article IV of the California Constitution and shall go into immediate effect.
4747
4848 The people of the State of California do enact as follows:
4949
5050 ## The people of the State of California do enact as follows:
5151
5252 SECTION 1. This act shall be known, and may be cited as, the Golden State Innovation Act of 2021.
5353
5454 SECTION 1. This act shall be known, and may be cited as, the Golden State Innovation Act of 2021.
5555
5656 SECTION 1. This act shall be known, and may be cited as, the Golden State Innovation Act of 2021.
5757
5858 ### SECTION 1.
5959
60-SEC. 2. Section 17039.3 of the Revenue and Taxation Code is amended to read:17039.3. (a) Notwithstanding any provision of this part or Part 10.2 (commencing with Section 18401) to the contrary, for taxpayers not required to be included in a combined report under Section 25101 or 25110, or taxpayers not authorized to be included in a combined report under Section 25101.15, for each taxable year beginning on or after January 1, 2020, and before January 1, 2023, the total of all business credits otherwise allowable under any provision of Chapter 2 (commencing with Section 17041), including the carryover of any business credit under a former provision of that chapter, for the taxable year shall not reduce the net tax, as defined in Section 17039, by more than five million dollars ($5,000,000).(b) Notwithstanding any provision of this part or Part 10.2 (commencing with Section 18401) to the contrary, for taxpayers required to be included in a combined report under Section 25101 or 25110, or taxpayers authorized to be included in a combined report under Section 25101.15, for each taxable year beginning on or after January 1, 2020, and before January 1, 2023, the total of all business credits otherwise allowable under any provision of Chapter 2 (commencing with Section 17041), including the carryover of any business credit under a former provision of that chapter, by all members of the combined report shall not reduce the aggregate amount of tax, as defined in Section 23036, of all members of the combined report by more than five million dollars ($5,000,000).(c) For purposes of this section, business credit means a credit allowable under any provision of Chapter 2 (commencing with Section 17041) other than the following credits:(1) The credit allowed by Section 17052 (relating to credit for earned income).(2) The credit allowed by Section 17052.1 (relating to credit for young child).(3) The credit allowed by Section 17052.6 (relating to credit for household and dependent care).(4) The credit allowed by Section 17052.25 (relating to credit for adoption costs).(5) The credit allowed by Section 17053.5 (relating to renters tax credit).(6) The credit allowed by Section 17054 (relating to credit for personal exemption).(7) The credit allowed by Section 17054.5 (relating to credit for qualified joint custody head of household and a qualified taxpayer with a dependent parent).(8) The credit allowed by Section 17054.7 (relating to credit for qualified senior head of household).(9) The credit allowed by Section 17058 (relating to credit for low-income housing).(10) The credit allowed by Section 17061 (relating to refunds pursuant to the Unemployment Insurance Code).(d) Any amounts included in an election pursuant to Section 6902.5, relating to an irrevocable election to apply credit amounts under Section 17053.85, 17053.95, 17053.98, 23685, 23695, or 23698 against qualified sales and use tax, as defined in Section 6902.5, are not included in the five-million-dollar ($5,000,000) limitation set forth in subdivision (a) or (b).(e) The amount of any credit otherwise allowable for the taxable year under Section 17039 that is not allowed due to application of this section shall remain a credit carryover amount under this part.(f) The carryover period for any credit that is not allowed due to the application of this section shall be increased by the number of taxable years the credit or any portion thereof was not allowed.(g) Notwithstanding anything to the contrary in this part or Part 10.2 (commencing with Section 18401), the credits listed in subdivision (c) shall be applied after any business credits, as limited by subdivision (a) or (b), are applied.(h) Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code does not apply to any standard, criterion, procedure, determination, rule, notice, or guideline established or issued by the Franchise Tax Board pursuant to this section.(i) For taxable years beginning on or after January 1, 2021, and before January 2, 1, 2023, the five-million-dollar ($5,000,000) limitation set forth in subdivision (a) or (b) shall not apply to taxpayers that perform clinical, biomedical, or other research, development, or testing needed for COVID-19 or other diseases. research and development in biotechnology. A taxpayer performs research and development in biotechnology if the taxpayer is described in Code 325414 or 541714 of the 2017 edition of the North American Industry Classification System (NAICS) published by the United States Office of Management and Budget.
60+SEC. 2. Section 17039.3 of the Revenue and Taxation Code is amended to read:17039.3. (a) Notwithstanding any provision of this part or Part 10.2 (commencing with Section 18401) to the contrary, for taxpayers not required to be included in a combined report under Section 25101 or 25110, or taxpayers not authorized to be included in a combined report under Section 25101.15, for each taxable year beginning on or after January 1, 2020, and before January 1, 2023, the total of all business credits otherwise allowable under any provision of Chapter 2 (commencing with Section 17041), including the carryover of any business credit under a former provision of that chapter, for the taxable year shall not reduce the net tax, as defined in Section 17039, by more than five million dollars ($5,000,000).(b) Notwithstanding any provision of this part or Part 10.2 (commencing with Section 18401) to the contrary, for taxpayers required to be included in a combined report under Section 25101 or 25110, or taxpayers authorized to be included in a combined report under Section 25101.15, for each taxable year beginning on or after January 1, 2020, and before January 1, 2023, the total of all business credits otherwise allowable under any provision of Chapter 2 (commencing with Section 17041), including the carryover of any business credit under a former provision of that chapter, by all members of the combined report shall not reduce the aggregate amount of tax, as defined in Section 23036, of all members of the combined report by more than five million dollars ($5,000,000).(c) For purposes of this section, business credit means a credit allowable under any provision of Chapter 2 (commencing with Section 17041) other than the following credits:(1) The credit allowed by Section 17052 (relating to credit for earned income).(2) The credit allowed by Section 17052.1 (relating to credit for young child).(3) The credit allowed by Section 17052.6 (relating to credit for household and dependent care).(4) The credit allowed by Section 17052.25 (relating to credit for adoption costs).(5) The credit allowed by Section 17053.5 (relating to renters tax credit).(6) The credit allowed by Section 17054 (relating to credit for personal exemption).(7) The credit allowed by Section 17054.5 (relating to credit for qualified joint custody head of household and a qualified taxpayer with a dependent parent).(8) The credit allowed by Section 17054.7 (relating to credit for qualified senior head of household).(9) The credit allowed by Section 17058 (relating to credit for low-income housing).(10) The credit allowed by Section 17061 (relating to refunds pursuant to the Unemployment Insurance Code).(d) Any amounts included in an election pursuant to Section 6902.5, relating to an irrevocable election to apply credit amounts under Section 17053.85, 17053.95, 17053.98, 23685, 23695, or 23698 against qualified sales and use tax, as defined in Section 6902.5, are not included in the five-million-dollar ($5,000,000) limitation set forth in subdivision (a) or (b).(e) The amount of any credit otherwise allowable for the taxable year under Section 17039 that is not allowed due to application of this section shall remain a credit carryover amount under this part.(f) The carryover period for any credit that is not allowed due to the application of this section shall be increased by the number of taxable years the credit or any portion thereof was not allowed.(g) Notwithstanding anything to the contrary in this part or Part 10.2 (commencing with Section 18401), the credits listed in subdivision (c) shall be applied after any business credits, as limited by subdivision (a) or (b), are applied.(h) Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code does not apply to any standard, criterion, procedure, determination, rule, notice, or guideline established or issued by the Franchise Tax Board pursuant to this section.(i) For taxable years on or after January 1, 2021, and before January 2, 2023, the five-million-dollar ($5,000,000) limitation set forth in subdivision (a) or (b) shall not apply to taxpayers that perform clinical, biomedical, or other research, development, or testing needed for COVID-19 or other diseases.
6161
6262 SEC. 2. Section 17039.3 of the Revenue and Taxation Code is amended to read:
6363
6464 ### SEC. 2.
6565
66-17039.3. (a) Notwithstanding any provision of this part or Part 10.2 (commencing with Section 18401) to the contrary, for taxpayers not required to be included in a combined report under Section 25101 or 25110, or taxpayers not authorized to be included in a combined report under Section 25101.15, for each taxable year beginning on or after January 1, 2020, and before January 1, 2023, the total of all business credits otherwise allowable under any provision of Chapter 2 (commencing with Section 17041), including the carryover of any business credit under a former provision of that chapter, for the taxable year shall not reduce the net tax, as defined in Section 17039, by more than five million dollars ($5,000,000).(b) Notwithstanding any provision of this part or Part 10.2 (commencing with Section 18401) to the contrary, for taxpayers required to be included in a combined report under Section 25101 or 25110, or taxpayers authorized to be included in a combined report under Section 25101.15, for each taxable year beginning on or after January 1, 2020, and before January 1, 2023, the total of all business credits otherwise allowable under any provision of Chapter 2 (commencing with Section 17041), including the carryover of any business credit under a former provision of that chapter, by all members of the combined report shall not reduce the aggregate amount of tax, as defined in Section 23036, of all members of the combined report by more than five million dollars ($5,000,000).(c) For purposes of this section, business credit means a credit allowable under any provision of Chapter 2 (commencing with Section 17041) other than the following credits:(1) The credit allowed by Section 17052 (relating to credit for earned income).(2) The credit allowed by Section 17052.1 (relating to credit for young child).(3) The credit allowed by Section 17052.6 (relating to credit for household and dependent care).(4) The credit allowed by Section 17052.25 (relating to credit for adoption costs).(5) The credit allowed by Section 17053.5 (relating to renters tax credit).(6) The credit allowed by Section 17054 (relating to credit for personal exemption).(7) The credit allowed by Section 17054.5 (relating to credit for qualified joint custody head of household and a qualified taxpayer with a dependent parent).(8) The credit allowed by Section 17054.7 (relating to credit for qualified senior head of household).(9) The credit allowed by Section 17058 (relating to credit for low-income housing).(10) The credit allowed by Section 17061 (relating to refunds pursuant to the Unemployment Insurance Code).(d) Any amounts included in an election pursuant to Section 6902.5, relating to an irrevocable election to apply credit amounts under Section 17053.85, 17053.95, 17053.98, 23685, 23695, or 23698 against qualified sales and use tax, as defined in Section 6902.5, are not included in the five-million-dollar ($5,000,000) limitation set forth in subdivision (a) or (b).(e) The amount of any credit otherwise allowable for the taxable year under Section 17039 that is not allowed due to application of this section shall remain a credit carryover amount under this part.(f) The carryover period for any credit that is not allowed due to the application of this section shall be increased by the number of taxable years the credit or any portion thereof was not allowed.(g) Notwithstanding anything to the contrary in this part or Part 10.2 (commencing with Section 18401), the credits listed in subdivision (c) shall be applied after any business credits, as limited by subdivision (a) or (b), are applied.(h) Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code does not apply to any standard, criterion, procedure, determination, rule, notice, or guideline established or issued by the Franchise Tax Board pursuant to this section.(i) For taxable years beginning on or after January 1, 2021, and before January 2, 1, 2023, the five-million-dollar ($5,000,000) limitation set forth in subdivision (a) or (b) shall not apply to taxpayers that perform clinical, biomedical, or other research, development, or testing needed for COVID-19 or other diseases. research and development in biotechnology. A taxpayer performs research and development in biotechnology if the taxpayer is described in Code 325414 or 541714 of the 2017 edition of the North American Industry Classification System (NAICS) published by the United States Office of Management and Budget.
66+17039.3. (a) Notwithstanding any provision of this part or Part 10.2 (commencing with Section 18401) to the contrary, for taxpayers not required to be included in a combined report under Section 25101 or 25110, or taxpayers not authorized to be included in a combined report under Section 25101.15, for each taxable year beginning on or after January 1, 2020, and before January 1, 2023, the total of all business credits otherwise allowable under any provision of Chapter 2 (commencing with Section 17041), including the carryover of any business credit under a former provision of that chapter, for the taxable year shall not reduce the net tax, as defined in Section 17039, by more than five million dollars ($5,000,000).(b) Notwithstanding any provision of this part or Part 10.2 (commencing with Section 18401) to the contrary, for taxpayers required to be included in a combined report under Section 25101 or 25110, or taxpayers authorized to be included in a combined report under Section 25101.15, for each taxable year beginning on or after January 1, 2020, and before January 1, 2023, the total of all business credits otherwise allowable under any provision of Chapter 2 (commencing with Section 17041), including the carryover of any business credit under a former provision of that chapter, by all members of the combined report shall not reduce the aggregate amount of tax, as defined in Section 23036, of all members of the combined report by more than five million dollars ($5,000,000).(c) For purposes of this section, business credit means a credit allowable under any provision of Chapter 2 (commencing with Section 17041) other than the following credits:(1) The credit allowed by Section 17052 (relating to credit for earned income).(2) The credit allowed by Section 17052.1 (relating to credit for young child).(3) The credit allowed by Section 17052.6 (relating to credit for household and dependent care).(4) The credit allowed by Section 17052.25 (relating to credit for adoption costs).(5) The credit allowed by Section 17053.5 (relating to renters tax credit).(6) The credit allowed by Section 17054 (relating to credit for personal exemption).(7) The credit allowed by Section 17054.5 (relating to credit for qualified joint custody head of household and a qualified taxpayer with a dependent parent).(8) The credit allowed by Section 17054.7 (relating to credit for qualified senior head of household).(9) The credit allowed by Section 17058 (relating to credit for low-income housing).(10) The credit allowed by Section 17061 (relating to refunds pursuant to the Unemployment Insurance Code).(d) Any amounts included in an election pursuant to Section 6902.5, relating to an irrevocable election to apply credit amounts under Section 17053.85, 17053.95, 17053.98, 23685, 23695, or 23698 against qualified sales and use tax, as defined in Section 6902.5, are not included in the five-million-dollar ($5,000,000) limitation set forth in subdivision (a) or (b).(e) The amount of any credit otherwise allowable for the taxable year under Section 17039 that is not allowed due to application of this section shall remain a credit carryover amount under this part.(f) The carryover period for any credit that is not allowed due to the application of this section shall be increased by the number of taxable years the credit or any portion thereof was not allowed.(g) Notwithstanding anything to the contrary in this part or Part 10.2 (commencing with Section 18401), the credits listed in subdivision (c) shall be applied after any business credits, as limited by subdivision (a) or (b), are applied.(h) Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code does not apply to any standard, criterion, procedure, determination, rule, notice, or guideline established or issued by the Franchise Tax Board pursuant to this section.(i) For taxable years on or after January 1, 2021, and before January 2, 2023, the five-million-dollar ($5,000,000) limitation set forth in subdivision (a) or (b) shall not apply to taxpayers that perform clinical, biomedical, or other research, development, or testing needed for COVID-19 or other diseases.
6767
68-17039.3. (a) Notwithstanding any provision of this part or Part 10.2 (commencing with Section 18401) to the contrary, for taxpayers not required to be included in a combined report under Section 25101 or 25110, or taxpayers not authorized to be included in a combined report under Section 25101.15, for each taxable year beginning on or after January 1, 2020, and before January 1, 2023, the total of all business credits otherwise allowable under any provision of Chapter 2 (commencing with Section 17041), including the carryover of any business credit under a former provision of that chapter, for the taxable year shall not reduce the net tax, as defined in Section 17039, by more than five million dollars ($5,000,000).(b) Notwithstanding any provision of this part or Part 10.2 (commencing with Section 18401) to the contrary, for taxpayers required to be included in a combined report under Section 25101 or 25110, or taxpayers authorized to be included in a combined report under Section 25101.15, for each taxable year beginning on or after January 1, 2020, and before January 1, 2023, the total of all business credits otherwise allowable under any provision of Chapter 2 (commencing with Section 17041), including the carryover of any business credit under a former provision of that chapter, by all members of the combined report shall not reduce the aggregate amount of tax, as defined in Section 23036, of all members of the combined report by more than five million dollars ($5,000,000).(c) For purposes of this section, business credit means a credit allowable under any provision of Chapter 2 (commencing with Section 17041) other than the following credits:(1) The credit allowed by Section 17052 (relating to credit for earned income).(2) The credit allowed by Section 17052.1 (relating to credit for young child).(3) The credit allowed by Section 17052.6 (relating to credit for household and dependent care).(4) The credit allowed by Section 17052.25 (relating to credit for adoption costs).(5) The credit allowed by Section 17053.5 (relating to renters tax credit).(6) The credit allowed by Section 17054 (relating to credit for personal exemption).(7) The credit allowed by Section 17054.5 (relating to credit for qualified joint custody head of household and a qualified taxpayer with a dependent parent).(8) The credit allowed by Section 17054.7 (relating to credit for qualified senior head of household).(9) The credit allowed by Section 17058 (relating to credit for low-income housing).(10) The credit allowed by Section 17061 (relating to refunds pursuant to the Unemployment Insurance Code).(d) Any amounts included in an election pursuant to Section 6902.5, relating to an irrevocable election to apply credit amounts under Section 17053.85, 17053.95, 17053.98, 23685, 23695, or 23698 against qualified sales and use tax, as defined in Section 6902.5, are not included in the five-million-dollar ($5,000,000) limitation set forth in subdivision (a) or (b).(e) The amount of any credit otherwise allowable for the taxable year under Section 17039 that is not allowed due to application of this section shall remain a credit carryover amount under this part.(f) The carryover period for any credit that is not allowed due to the application of this section shall be increased by the number of taxable years the credit or any portion thereof was not allowed.(g) Notwithstanding anything to the contrary in this part or Part 10.2 (commencing with Section 18401), the credits listed in subdivision (c) shall be applied after any business credits, as limited by subdivision (a) or (b), are applied.(h) Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code does not apply to any standard, criterion, procedure, determination, rule, notice, or guideline established or issued by the Franchise Tax Board pursuant to this section.(i) For taxable years beginning on or after January 1, 2021, and before January 2, 1, 2023, the five-million-dollar ($5,000,000) limitation set forth in subdivision (a) or (b) shall not apply to taxpayers that perform clinical, biomedical, or other research, development, or testing needed for COVID-19 or other diseases. research and development in biotechnology. A taxpayer performs research and development in biotechnology if the taxpayer is described in Code 325414 or 541714 of the 2017 edition of the North American Industry Classification System (NAICS) published by the United States Office of Management and Budget.
68+17039.3. (a) Notwithstanding any provision of this part or Part 10.2 (commencing with Section 18401) to the contrary, for taxpayers not required to be included in a combined report under Section 25101 or 25110, or taxpayers not authorized to be included in a combined report under Section 25101.15, for each taxable year beginning on or after January 1, 2020, and before January 1, 2023, the total of all business credits otherwise allowable under any provision of Chapter 2 (commencing with Section 17041), including the carryover of any business credit under a former provision of that chapter, for the taxable year shall not reduce the net tax, as defined in Section 17039, by more than five million dollars ($5,000,000).(b) Notwithstanding any provision of this part or Part 10.2 (commencing with Section 18401) to the contrary, for taxpayers required to be included in a combined report under Section 25101 or 25110, or taxpayers authorized to be included in a combined report under Section 25101.15, for each taxable year beginning on or after January 1, 2020, and before January 1, 2023, the total of all business credits otherwise allowable under any provision of Chapter 2 (commencing with Section 17041), including the carryover of any business credit under a former provision of that chapter, by all members of the combined report shall not reduce the aggregate amount of tax, as defined in Section 23036, of all members of the combined report by more than five million dollars ($5,000,000).(c) For purposes of this section, business credit means a credit allowable under any provision of Chapter 2 (commencing with Section 17041) other than the following credits:(1) The credit allowed by Section 17052 (relating to credit for earned income).(2) The credit allowed by Section 17052.1 (relating to credit for young child).(3) The credit allowed by Section 17052.6 (relating to credit for household and dependent care).(4) The credit allowed by Section 17052.25 (relating to credit for adoption costs).(5) The credit allowed by Section 17053.5 (relating to renters tax credit).(6) The credit allowed by Section 17054 (relating to credit for personal exemption).(7) The credit allowed by Section 17054.5 (relating to credit for qualified joint custody head of household and a qualified taxpayer with a dependent parent).(8) The credit allowed by Section 17054.7 (relating to credit for qualified senior head of household).(9) The credit allowed by Section 17058 (relating to credit for low-income housing).(10) The credit allowed by Section 17061 (relating to refunds pursuant to the Unemployment Insurance Code).(d) Any amounts included in an election pursuant to Section 6902.5, relating to an irrevocable election to apply credit amounts under Section 17053.85, 17053.95, 17053.98, 23685, 23695, or 23698 against qualified sales and use tax, as defined in Section 6902.5, are not included in the five-million-dollar ($5,000,000) limitation set forth in subdivision (a) or (b).(e) The amount of any credit otherwise allowable for the taxable year under Section 17039 that is not allowed due to application of this section shall remain a credit carryover amount under this part.(f) The carryover period for any credit that is not allowed due to the application of this section shall be increased by the number of taxable years the credit or any portion thereof was not allowed.(g) Notwithstanding anything to the contrary in this part or Part 10.2 (commencing with Section 18401), the credits listed in subdivision (c) shall be applied after any business credits, as limited by subdivision (a) or (b), are applied.(h) Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code does not apply to any standard, criterion, procedure, determination, rule, notice, or guideline established or issued by the Franchise Tax Board pursuant to this section.(i) For taxable years on or after January 1, 2021, and before January 2, 2023, the five-million-dollar ($5,000,000) limitation set forth in subdivision (a) or (b) shall not apply to taxpayers that perform clinical, biomedical, or other research, development, or testing needed for COVID-19 or other diseases.
6969
70-17039.3. (a) Notwithstanding any provision of this part or Part 10.2 (commencing with Section 18401) to the contrary, for taxpayers not required to be included in a combined report under Section 25101 or 25110, or taxpayers not authorized to be included in a combined report under Section 25101.15, for each taxable year beginning on or after January 1, 2020, and before January 1, 2023, the total of all business credits otherwise allowable under any provision of Chapter 2 (commencing with Section 17041), including the carryover of any business credit under a former provision of that chapter, for the taxable year shall not reduce the net tax, as defined in Section 17039, by more than five million dollars ($5,000,000).(b) Notwithstanding any provision of this part or Part 10.2 (commencing with Section 18401) to the contrary, for taxpayers required to be included in a combined report under Section 25101 or 25110, or taxpayers authorized to be included in a combined report under Section 25101.15, for each taxable year beginning on or after January 1, 2020, and before January 1, 2023, the total of all business credits otherwise allowable under any provision of Chapter 2 (commencing with Section 17041), including the carryover of any business credit under a former provision of that chapter, by all members of the combined report shall not reduce the aggregate amount of tax, as defined in Section 23036, of all members of the combined report by more than five million dollars ($5,000,000).(c) For purposes of this section, business credit means a credit allowable under any provision of Chapter 2 (commencing with Section 17041) other than the following credits:(1) The credit allowed by Section 17052 (relating to credit for earned income).(2) The credit allowed by Section 17052.1 (relating to credit for young child).(3) The credit allowed by Section 17052.6 (relating to credit for household and dependent care).(4) The credit allowed by Section 17052.25 (relating to credit for adoption costs).(5) The credit allowed by Section 17053.5 (relating to renters tax credit).(6) The credit allowed by Section 17054 (relating to credit for personal exemption).(7) The credit allowed by Section 17054.5 (relating to credit for qualified joint custody head of household and a qualified taxpayer with a dependent parent).(8) The credit allowed by Section 17054.7 (relating to credit for qualified senior head of household).(9) The credit allowed by Section 17058 (relating to credit for low-income housing).(10) The credit allowed by Section 17061 (relating to refunds pursuant to the Unemployment Insurance Code).(d) Any amounts included in an election pursuant to Section 6902.5, relating to an irrevocable election to apply credit amounts under Section 17053.85, 17053.95, 17053.98, 23685, 23695, or 23698 against qualified sales and use tax, as defined in Section 6902.5, are not included in the five-million-dollar ($5,000,000) limitation set forth in subdivision (a) or (b).(e) The amount of any credit otherwise allowable for the taxable year under Section 17039 that is not allowed due to application of this section shall remain a credit carryover amount under this part.(f) The carryover period for any credit that is not allowed due to the application of this section shall be increased by the number of taxable years the credit or any portion thereof was not allowed.(g) Notwithstanding anything to the contrary in this part or Part 10.2 (commencing with Section 18401), the credits listed in subdivision (c) shall be applied after any business credits, as limited by subdivision (a) or (b), are applied.(h) Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code does not apply to any standard, criterion, procedure, determination, rule, notice, or guideline established or issued by the Franchise Tax Board pursuant to this section.(i) For taxable years beginning on or after January 1, 2021, and before January 2, 1, 2023, the five-million-dollar ($5,000,000) limitation set forth in subdivision (a) or (b) shall not apply to taxpayers that perform clinical, biomedical, or other research, development, or testing needed for COVID-19 or other diseases. research and development in biotechnology. A taxpayer performs research and development in biotechnology if the taxpayer is described in Code 325414 or 541714 of the 2017 edition of the North American Industry Classification System (NAICS) published by the United States Office of Management and Budget.
70+17039.3. (a) Notwithstanding any provision of this part or Part 10.2 (commencing with Section 18401) to the contrary, for taxpayers not required to be included in a combined report under Section 25101 or 25110, or taxpayers not authorized to be included in a combined report under Section 25101.15, for each taxable year beginning on or after January 1, 2020, and before January 1, 2023, the total of all business credits otherwise allowable under any provision of Chapter 2 (commencing with Section 17041), including the carryover of any business credit under a former provision of that chapter, for the taxable year shall not reduce the net tax, as defined in Section 17039, by more than five million dollars ($5,000,000).(b) Notwithstanding any provision of this part or Part 10.2 (commencing with Section 18401) to the contrary, for taxpayers required to be included in a combined report under Section 25101 or 25110, or taxpayers authorized to be included in a combined report under Section 25101.15, for each taxable year beginning on or after January 1, 2020, and before January 1, 2023, the total of all business credits otherwise allowable under any provision of Chapter 2 (commencing with Section 17041), including the carryover of any business credit under a former provision of that chapter, by all members of the combined report shall not reduce the aggregate amount of tax, as defined in Section 23036, of all members of the combined report by more than five million dollars ($5,000,000).(c) For purposes of this section, business credit means a credit allowable under any provision of Chapter 2 (commencing with Section 17041) other than the following credits:(1) The credit allowed by Section 17052 (relating to credit for earned income).(2) The credit allowed by Section 17052.1 (relating to credit for young child).(3) The credit allowed by Section 17052.6 (relating to credit for household and dependent care).(4) The credit allowed by Section 17052.25 (relating to credit for adoption costs).(5) The credit allowed by Section 17053.5 (relating to renters tax credit).(6) The credit allowed by Section 17054 (relating to credit for personal exemption).(7) The credit allowed by Section 17054.5 (relating to credit for qualified joint custody head of household and a qualified taxpayer with a dependent parent).(8) The credit allowed by Section 17054.7 (relating to credit for qualified senior head of household).(9) The credit allowed by Section 17058 (relating to credit for low-income housing).(10) The credit allowed by Section 17061 (relating to refunds pursuant to the Unemployment Insurance Code).(d) Any amounts included in an election pursuant to Section 6902.5, relating to an irrevocable election to apply credit amounts under Section 17053.85, 17053.95, 17053.98, 23685, 23695, or 23698 against qualified sales and use tax, as defined in Section 6902.5, are not included in the five-million-dollar ($5,000,000) limitation set forth in subdivision (a) or (b).(e) The amount of any credit otherwise allowable for the taxable year under Section 17039 that is not allowed due to application of this section shall remain a credit carryover amount under this part.(f) The carryover period for any credit that is not allowed due to the application of this section shall be increased by the number of taxable years the credit or any portion thereof was not allowed.(g) Notwithstanding anything to the contrary in this part or Part 10.2 (commencing with Section 18401), the credits listed in subdivision (c) shall be applied after any business credits, as limited by subdivision (a) or (b), are applied.(h) Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code does not apply to any standard, criterion, procedure, determination, rule, notice, or guideline established or issued by the Franchise Tax Board pursuant to this section.(i) For taxable years on or after January 1, 2021, and before January 2, 2023, the five-million-dollar ($5,000,000) limitation set forth in subdivision (a) or (b) shall not apply to taxpayers that perform clinical, biomedical, or other research, development, or testing needed for COVID-19 or other diseases.
7171
7272
7373
7474 17039.3. (a) Notwithstanding any provision of this part or Part 10.2 (commencing with Section 18401) to the contrary, for taxpayers not required to be included in a combined report under Section 25101 or 25110, or taxpayers not authorized to be included in a combined report under Section 25101.15, for each taxable year beginning on or after January 1, 2020, and before January 1, 2023, the total of all business credits otherwise allowable under any provision of Chapter 2 (commencing with Section 17041), including the carryover of any business credit under a former provision of that chapter, for the taxable year shall not reduce the net tax, as defined in Section 17039, by more than five million dollars ($5,000,000).
7575
7676 (b) Notwithstanding any provision of this part or Part 10.2 (commencing with Section 18401) to the contrary, for taxpayers required to be included in a combined report under Section 25101 or 25110, or taxpayers authorized to be included in a combined report under Section 25101.15, for each taxable year beginning on or after January 1, 2020, and before January 1, 2023, the total of all business credits otherwise allowable under any provision of Chapter 2 (commencing with Section 17041), including the carryover of any business credit under a former provision of that chapter, by all members of the combined report shall not reduce the aggregate amount of tax, as defined in Section 23036, of all members of the combined report by more than five million dollars ($5,000,000).
7777
7878 (c) For purposes of this section, business credit means a credit allowable under any provision of Chapter 2 (commencing with Section 17041) other than the following credits:
7979
8080 (1) The credit allowed by Section 17052 (relating to credit for earned income).
8181
8282 (2) The credit allowed by Section 17052.1 (relating to credit for young child).
8383
8484 (3) The credit allowed by Section 17052.6 (relating to credit for household and dependent care).
8585
8686 (4) The credit allowed by Section 17052.25 (relating to credit for adoption costs).
8787
8888 (5) The credit allowed by Section 17053.5 (relating to renters tax credit).
8989
9090 (6) The credit allowed by Section 17054 (relating to credit for personal exemption).
9191
9292 (7) The credit allowed by Section 17054.5 (relating to credit for qualified joint custody head of household and a qualified taxpayer with a dependent parent).
9393
9494 (8) The credit allowed by Section 17054.7 (relating to credit for qualified senior head of household).
9595
9696 (9) The credit allowed by Section 17058 (relating to credit for low-income housing).
9797
9898 (10) The credit allowed by Section 17061 (relating to refunds pursuant to the Unemployment Insurance Code).
9999
100100 (d) Any amounts included in an election pursuant to Section 6902.5, relating to an irrevocable election to apply credit amounts under Section 17053.85, 17053.95, 17053.98, 23685, 23695, or 23698 against qualified sales and use tax, as defined in Section 6902.5, are not included in the five-million-dollar ($5,000,000) limitation set forth in subdivision (a) or (b).
101101
102102 (e) The amount of any credit otherwise allowable for the taxable year under Section 17039 that is not allowed due to application of this section shall remain a credit carryover amount under this part.
103103
104104 (f) The carryover period for any credit that is not allowed due to the application of this section shall be increased by the number of taxable years the credit or any portion thereof was not allowed.
105105
106106 (g) Notwithstanding anything to the contrary in this part or Part 10.2 (commencing with Section 18401), the credits listed in subdivision (c) shall be applied after any business credits, as limited by subdivision (a) or (b), are applied.
107107
108108 (h) Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code does not apply to any standard, criterion, procedure, determination, rule, notice, or guideline established or issued by the Franchise Tax Board pursuant to this section.
109109
110-(i) For taxable years beginning on or after January 1, 2021, and before January 2, 1, 2023, the five-million-dollar ($5,000,000) limitation set forth in subdivision (a) or (b) shall not apply to taxpayers that perform clinical, biomedical, or other research, development, or testing needed for COVID-19 or other diseases. research and development in biotechnology. A taxpayer performs research and development in biotechnology if the taxpayer is described in Code 325414 or 541714 of the 2017 edition of the North American Industry Classification System (NAICS) published by the United States Office of Management and Budget.
110+(i) For taxable years on or after January 1, 2021, and before January 2, 2023, the five-million-dollar ($5,000,000) limitation set forth in subdivision (a) or (b) shall not apply to taxpayers that perform clinical, biomedical, or other research, development, or testing needed for COVID-19 or other diseases.
111111
112-SEC. 3. Section 17276.23 of the Revenue and Taxation Code is amended to read:17276.23. (a) Notwithstanding Sections 17276, 17276.1, 17276.4, 17276.7, and 17276.22, former Sections 17276.2, 17276.5, 17276.6, and 17276.20, and Section 172 of the Internal Revenue Code, a net operating loss deduction shall not be allowed for any taxable year beginning on or after January 1, 2020, and before January 1, 2023.(b) For any net operating loss or carryover of a net operating loss for which a deduction is denied by subdivision (a), the carryover period under Section 172 of the Internal Revenue Code shall be extended as follows:(1) By one year, for losses incurred in taxable years beginning on or after January 1, 2021, and before January 1, 2022.(2) By two years, for losses incurred in taxable years beginning on or after January 1, 2020, and before January 1, 2021.(3) By three years, for losses incurred in taxable years beginning before January 1, 2020.(c) This section shall not apply as follows:(1) For a taxable year beginning on or after January 1, 2020, and before January 1, 2023, this section shall not apply to a taxpayer with a net business income of less than one million dollars ($1,000,000) for the taxable year.(2) For a taxable year beginning on or after January 1, 2020, and before January 1, 2023, this section shall not apply to a taxpayer with a modified adjusted gross income of less than one million dollars ($1,000,000) for the taxable year.(3) For a taxable years year beginning on or after January 1, 2021, and before January 1, 2023, this section shall not apply to a taxpayer that perform clinical, biomedical, and other research, development, and testing needed for COVID-19 or other diseases. performs research and development in biotechnology. A taxpayer performs research and development in biotechnology if the taxpayer is described in Code 325414 or 541714 of the 2017 edition of the North American Industry Classification System (NAICS) published by the United States Office of Management and Budget.(d) For purposes of this section:(1) Business income means any of the following:(A) Income from a trade or business, whether conducted by the taxpayer or by a passthrough entity owned directly or indirectly by the taxpayer.(B) Income from rental activity.(C) Income attributable to a farming business.(2) Modified adjusted gross income means the amount described in paragraph (2) of subdivision (h) of Section 17024.5, determined without regard to the deduction allowed under Section 172 of the Internal Revenue Code, relating to net operating loss deduction.(3) Passthrough entity means a partnership or an S S corporation.
112+SEC. 3. Section 17276.23 of the Revenue and Taxation Code is amended to read:17276.23. (a) Notwithstanding Sections 17276, 17276.1, 17276.4, 17276.7, and 17276.22, former Sections 17276.2, 17276.5, 17276.6, and 17276.20, and Section 172 of the Internal Revenue Code, a net operating loss deduction shall not be allowed for any taxable year beginning on or after January 1, 2020, and before January 1, 2023.(b) For any net operating loss or carryover of a net operating loss for which a deduction is denied by subdivision (a), the carryover period under Section 172 of the Internal Revenue Code shall be extended as follows:(1) By one year, for losses incurred in taxable years beginning on or after January 1, 2021, and before January 1, 2022.(2) By two years, for losses incurred in taxable years beginning on or after January 1, 2020, and before January 1, 2021.(3) By three years, for losses incurred in taxable years beginning before January 1, 2020.(c) This section shall not apply as follows:(1) For a taxable year beginning on or after January 1, 2020, and before January 1, 2023, this section shall not apply to a taxpayer with a net business income of less than one million dollars ($1,000,000) for the taxable year.(2) For a taxable year beginning on or after January 1, 2020, and before January 1, 2023, this section shall not apply to a taxpayer with a modified adjusted gross income of less than one million dollars ($1,000,000) for the taxable year.(3) For a taxable years beginning on or after January 1, 2021, and before January 1, 2023, this section shall not apply to a taxpayer that perform clinical, biomedical, and other research, development, and testing needed for COVID-19 or other diseases.(d) For purposes of this section:(1) Business income means any of the following:(A) Income from a trade or business, whether conducted by the taxpayer or by a passthrough entity owned directly or indirectly by the taxpayer.(B) Income from rental activity.(C) Income attributable to a farming business.(2) Modified adjusted gross income means the amount described in paragraph (2) of subdivision (h) of Section 17024.5, determined without regard to the deduction allowed under Section 172 of the Internal Revenue Code, relating to net operating loss deduction.(3) Passthrough entity means a partnership or an S corporation.
113113
114114 SEC. 3. Section 17276.23 of the Revenue and Taxation Code is amended to read:
115115
116116 ### SEC. 3.
117117
118-17276.23. (a) Notwithstanding Sections 17276, 17276.1, 17276.4, 17276.7, and 17276.22, former Sections 17276.2, 17276.5, 17276.6, and 17276.20, and Section 172 of the Internal Revenue Code, a net operating loss deduction shall not be allowed for any taxable year beginning on or after January 1, 2020, and before January 1, 2023.(b) For any net operating loss or carryover of a net operating loss for which a deduction is denied by subdivision (a), the carryover period under Section 172 of the Internal Revenue Code shall be extended as follows:(1) By one year, for losses incurred in taxable years beginning on or after January 1, 2021, and before January 1, 2022.(2) By two years, for losses incurred in taxable years beginning on or after January 1, 2020, and before January 1, 2021.(3) By three years, for losses incurred in taxable years beginning before January 1, 2020.(c) This section shall not apply as follows:(1) For a taxable year beginning on or after January 1, 2020, and before January 1, 2023, this section shall not apply to a taxpayer with a net business income of less than one million dollars ($1,000,000) for the taxable year.(2) For a taxable year beginning on or after January 1, 2020, and before January 1, 2023, this section shall not apply to a taxpayer with a modified adjusted gross income of less than one million dollars ($1,000,000) for the taxable year.(3) For a taxable years year beginning on or after January 1, 2021, and before January 1, 2023, this section shall not apply to a taxpayer that perform clinical, biomedical, and other research, development, and testing needed for COVID-19 or other diseases. performs research and development in biotechnology. A taxpayer performs research and development in biotechnology if the taxpayer is described in Code 325414 or 541714 of the 2017 edition of the North American Industry Classification System (NAICS) published by the United States Office of Management and Budget.(d) For purposes of this section:(1) Business income means any of the following:(A) Income from a trade or business, whether conducted by the taxpayer or by a passthrough entity owned directly or indirectly by the taxpayer.(B) Income from rental activity.(C) Income attributable to a farming business.(2) Modified adjusted gross income means the amount described in paragraph (2) of subdivision (h) of Section 17024.5, determined without regard to the deduction allowed under Section 172 of the Internal Revenue Code, relating to net operating loss deduction.(3) Passthrough entity means a partnership or an S S corporation.
118+17276.23. (a) Notwithstanding Sections 17276, 17276.1, 17276.4, 17276.7, and 17276.22, former Sections 17276.2, 17276.5, 17276.6, and 17276.20, and Section 172 of the Internal Revenue Code, a net operating loss deduction shall not be allowed for any taxable year beginning on or after January 1, 2020, and before January 1, 2023.(b) For any net operating loss or carryover of a net operating loss for which a deduction is denied by subdivision (a), the carryover period under Section 172 of the Internal Revenue Code shall be extended as follows:(1) By one year, for losses incurred in taxable years beginning on or after January 1, 2021, and before January 1, 2022.(2) By two years, for losses incurred in taxable years beginning on or after January 1, 2020, and before January 1, 2021.(3) By three years, for losses incurred in taxable years beginning before January 1, 2020.(c) This section shall not apply as follows:(1) For a taxable year beginning on or after January 1, 2020, and before January 1, 2023, this section shall not apply to a taxpayer with a net business income of less than one million dollars ($1,000,000) for the taxable year.(2) For a taxable year beginning on or after January 1, 2020, and before January 1, 2023, this section shall not apply to a taxpayer with a modified adjusted gross income of less than one million dollars ($1,000,000) for the taxable year.(3) For a taxable years beginning on or after January 1, 2021, and before January 1, 2023, this section shall not apply to a taxpayer that perform clinical, biomedical, and other research, development, and testing needed for COVID-19 or other diseases.(d) For purposes of this section:(1) Business income means any of the following:(A) Income from a trade or business, whether conducted by the taxpayer or by a passthrough entity owned directly or indirectly by the taxpayer.(B) Income from rental activity.(C) Income attributable to a farming business.(2) Modified adjusted gross income means the amount described in paragraph (2) of subdivision (h) of Section 17024.5, determined without regard to the deduction allowed under Section 172 of the Internal Revenue Code, relating to net operating loss deduction.(3) Passthrough entity means a partnership or an S corporation.
119119
120-17276.23. (a) Notwithstanding Sections 17276, 17276.1, 17276.4, 17276.7, and 17276.22, former Sections 17276.2, 17276.5, 17276.6, and 17276.20, and Section 172 of the Internal Revenue Code, a net operating loss deduction shall not be allowed for any taxable year beginning on or after January 1, 2020, and before January 1, 2023.(b) For any net operating loss or carryover of a net operating loss for which a deduction is denied by subdivision (a), the carryover period under Section 172 of the Internal Revenue Code shall be extended as follows:(1) By one year, for losses incurred in taxable years beginning on or after January 1, 2021, and before January 1, 2022.(2) By two years, for losses incurred in taxable years beginning on or after January 1, 2020, and before January 1, 2021.(3) By three years, for losses incurred in taxable years beginning before January 1, 2020.(c) This section shall not apply as follows:(1) For a taxable year beginning on or after January 1, 2020, and before January 1, 2023, this section shall not apply to a taxpayer with a net business income of less than one million dollars ($1,000,000) for the taxable year.(2) For a taxable year beginning on or after January 1, 2020, and before January 1, 2023, this section shall not apply to a taxpayer with a modified adjusted gross income of less than one million dollars ($1,000,000) for the taxable year.(3) For a taxable years year beginning on or after January 1, 2021, and before January 1, 2023, this section shall not apply to a taxpayer that perform clinical, biomedical, and other research, development, and testing needed for COVID-19 or other diseases. performs research and development in biotechnology. A taxpayer performs research and development in biotechnology if the taxpayer is described in Code 325414 or 541714 of the 2017 edition of the North American Industry Classification System (NAICS) published by the United States Office of Management and Budget.(d) For purposes of this section:(1) Business income means any of the following:(A) Income from a trade or business, whether conducted by the taxpayer or by a passthrough entity owned directly or indirectly by the taxpayer.(B) Income from rental activity.(C) Income attributable to a farming business.(2) Modified adjusted gross income means the amount described in paragraph (2) of subdivision (h) of Section 17024.5, determined without regard to the deduction allowed under Section 172 of the Internal Revenue Code, relating to net operating loss deduction.(3) Passthrough entity means a partnership or an S S corporation.
120+17276.23. (a) Notwithstanding Sections 17276, 17276.1, 17276.4, 17276.7, and 17276.22, former Sections 17276.2, 17276.5, 17276.6, and 17276.20, and Section 172 of the Internal Revenue Code, a net operating loss deduction shall not be allowed for any taxable year beginning on or after January 1, 2020, and before January 1, 2023.(b) For any net operating loss or carryover of a net operating loss for which a deduction is denied by subdivision (a), the carryover period under Section 172 of the Internal Revenue Code shall be extended as follows:(1) By one year, for losses incurred in taxable years beginning on or after January 1, 2021, and before January 1, 2022.(2) By two years, for losses incurred in taxable years beginning on or after January 1, 2020, and before January 1, 2021.(3) By three years, for losses incurred in taxable years beginning before January 1, 2020.(c) This section shall not apply as follows:(1) For a taxable year beginning on or after January 1, 2020, and before January 1, 2023, this section shall not apply to a taxpayer with a net business income of less than one million dollars ($1,000,000) for the taxable year.(2) For a taxable year beginning on or after January 1, 2020, and before January 1, 2023, this section shall not apply to a taxpayer with a modified adjusted gross income of less than one million dollars ($1,000,000) for the taxable year.(3) For a taxable years beginning on or after January 1, 2021, and before January 1, 2023, this section shall not apply to a taxpayer that perform clinical, biomedical, and other research, development, and testing needed for COVID-19 or other diseases.(d) For purposes of this section:(1) Business income means any of the following:(A) Income from a trade or business, whether conducted by the taxpayer or by a passthrough entity owned directly or indirectly by the taxpayer.(B) Income from rental activity.(C) Income attributable to a farming business.(2) Modified adjusted gross income means the amount described in paragraph (2) of subdivision (h) of Section 17024.5, determined without regard to the deduction allowed under Section 172 of the Internal Revenue Code, relating to net operating loss deduction.(3) Passthrough entity means a partnership or an S corporation.
121121
122-17276.23. (a) Notwithstanding Sections 17276, 17276.1, 17276.4, 17276.7, and 17276.22, former Sections 17276.2, 17276.5, 17276.6, and 17276.20, and Section 172 of the Internal Revenue Code, a net operating loss deduction shall not be allowed for any taxable year beginning on or after January 1, 2020, and before January 1, 2023.(b) For any net operating loss or carryover of a net operating loss for which a deduction is denied by subdivision (a), the carryover period under Section 172 of the Internal Revenue Code shall be extended as follows:(1) By one year, for losses incurred in taxable years beginning on or after January 1, 2021, and before January 1, 2022.(2) By two years, for losses incurred in taxable years beginning on or after January 1, 2020, and before January 1, 2021.(3) By three years, for losses incurred in taxable years beginning before January 1, 2020.(c) This section shall not apply as follows:(1) For a taxable year beginning on or after January 1, 2020, and before January 1, 2023, this section shall not apply to a taxpayer with a net business income of less than one million dollars ($1,000,000) for the taxable year.(2) For a taxable year beginning on or after January 1, 2020, and before January 1, 2023, this section shall not apply to a taxpayer with a modified adjusted gross income of less than one million dollars ($1,000,000) for the taxable year.(3) For a taxable years year beginning on or after January 1, 2021, and before January 1, 2023, this section shall not apply to a taxpayer that perform clinical, biomedical, and other research, development, and testing needed for COVID-19 or other diseases. performs research and development in biotechnology. A taxpayer performs research and development in biotechnology if the taxpayer is described in Code 325414 or 541714 of the 2017 edition of the North American Industry Classification System (NAICS) published by the United States Office of Management and Budget.(d) For purposes of this section:(1) Business income means any of the following:(A) Income from a trade or business, whether conducted by the taxpayer or by a passthrough entity owned directly or indirectly by the taxpayer.(B) Income from rental activity.(C) Income attributable to a farming business.(2) Modified adjusted gross income means the amount described in paragraph (2) of subdivision (h) of Section 17024.5, determined without regard to the deduction allowed under Section 172 of the Internal Revenue Code, relating to net operating loss deduction.(3) Passthrough entity means a partnership or an S S corporation.
122+17276.23. (a) Notwithstanding Sections 17276, 17276.1, 17276.4, 17276.7, and 17276.22, former Sections 17276.2, 17276.5, 17276.6, and 17276.20, and Section 172 of the Internal Revenue Code, a net operating loss deduction shall not be allowed for any taxable year beginning on or after January 1, 2020, and before January 1, 2023.(b) For any net operating loss or carryover of a net operating loss for which a deduction is denied by subdivision (a), the carryover period under Section 172 of the Internal Revenue Code shall be extended as follows:(1) By one year, for losses incurred in taxable years beginning on or after January 1, 2021, and before January 1, 2022.(2) By two years, for losses incurred in taxable years beginning on or after January 1, 2020, and before January 1, 2021.(3) By three years, for losses incurred in taxable years beginning before January 1, 2020.(c) This section shall not apply as follows:(1) For a taxable year beginning on or after January 1, 2020, and before January 1, 2023, this section shall not apply to a taxpayer with a net business income of less than one million dollars ($1,000,000) for the taxable year.(2) For a taxable year beginning on or after January 1, 2020, and before January 1, 2023, this section shall not apply to a taxpayer with a modified adjusted gross income of less than one million dollars ($1,000,000) for the taxable year.(3) For a taxable years beginning on or after January 1, 2021, and before January 1, 2023, this section shall not apply to a taxpayer that perform clinical, biomedical, and other research, development, and testing needed for COVID-19 or other diseases.(d) For purposes of this section:(1) Business income means any of the following:(A) Income from a trade or business, whether conducted by the taxpayer or by a passthrough entity owned directly or indirectly by the taxpayer.(B) Income from rental activity.(C) Income attributable to a farming business.(2) Modified adjusted gross income means the amount described in paragraph (2) of subdivision (h) of Section 17024.5, determined without regard to the deduction allowed under Section 172 of the Internal Revenue Code, relating to net operating loss deduction.(3) Passthrough entity means a partnership or an S corporation.
123123
124124
125125
126126 17276.23. (a) Notwithstanding Sections 17276, 17276.1, 17276.4, 17276.7, and 17276.22, former Sections 17276.2, 17276.5, 17276.6, and 17276.20, and Section 172 of the Internal Revenue Code, a net operating loss deduction shall not be allowed for any taxable year beginning on or after January 1, 2020, and before January 1, 2023.
127127
128128 (b) For any net operating loss or carryover of a net operating loss for which a deduction is denied by subdivision (a), the carryover period under Section 172 of the Internal Revenue Code shall be extended as follows:
129129
130130 (1) By one year, for losses incurred in taxable years beginning on or after January 1, 2021, and before January 1, 2022.
131131
132132 (2) By two years, for losses incurred in taxable years beginning on or after January 1, 2020, and before January 1, 2021.
133133
134134 (3) By three years, for losses incurred in taxable years beginning before January 1, 2020.
135135
136136 (c) This section shall not apply as follows:
137137
138138 (1) For a taxable year beginning on or after January 1, 2020, and before January 1, 2023, this section shall not apply to a taxpayer with a net business income of less than one million dollars ($1,000,000) for the taxable year.
139139
140140 (2) For a taxable year beginning on or after January 1, 2020, and before January 1, 2023, this section shall not apply to a taxpayer with a modified adjusted gross income of less than one million dollars ($1,000,000) for the taxable year.
141141
142-(3) For a taxable years year beginning on or after January 1, 2021, and before January 1, 2023, this section shall not apply to a taxpayer that perform clinical, biomedical, and other research, development, and testing needed for COVID-19 or other diseases. performs research and development in biotechnology. A taxpayer performs research and development in biotechnology if the taxpayer is described in Code 325414 or 541714 of the 2017 edition of the North American Industry Classification System (NAICS) published by the United States Office of Management and Budget.
142+(3) For a taxable years beginning on or after January 1, 2021, and before January 1, 2023, this section shall not apply to a taxpayer that perform clinical, biomedical, and other research, development, and testing needed for COVID-19 or other diseases.
143143
144144 (d) For purposes of this section:
145145
146146 (1) Business income means any of the following:
147147
148148 (A) Income from a trade or business, whether conducted by the taxpayer or by a passthrough entity owned directly or indirectly by the taxpayer.
149149
150150 (B) Income from rental activity.
151151
152152 (C) Income attributable to a farming business.
153153
154154 (2) Modified adjusted gross income means the amount described in paragraph (2) of subdivision (h) of Section 17024.5, determined without regard to the deduction allowed under Section 172 of the Internal Revenue Code, relating to net operating loss deduction.
155155
156-(3) Passthrough entity means a partnership or an S S corporation.
156+(3) Passthrough entity means a partnership or an S corporation.
157157
158-SEC. 4. Section 23036.3 of the Revenue and Taxation Code is amended to read:23036.3. (a) Notwithstanding any provision of this part or Part 10.2 (commencing with Section 18401) to the contrary, except as provided in subdivision (d), for taxpayers not required to be included in a combined report under Section 25101 or 25110, or taxpayers not authorized to be included in a combined report under Section 25101.15, for each taxable year beginning on or after January 1, 2020, and before January 1, 2023, the total of all credits otherwise allowable under any provision of Chapter 3.5 (commencing with Section 23604) including the carryover of any credit under a former provision of that chapter, for the taxable year shall not reduce the tax, as defined in Section 23036, by more than five million dollars ($5,000,000).(b) Notwithstanding any provision of this part or Part 10.2 (commencing with Section 18401) to the contrary, except as provided in subdivision (d), for taxpayers required to be included in a combined report under Section 25101 or 25110, or taxpayers authorized to be included in a combined report under Section 25101.15, for each taxable year beginning on or after January 1, 2020, and before January 1, 2023, the total of all credits otherwise allowable under any provision of Chapter 3.5 (commencing with Section 23604), including the carryover of any credit under a former provision of that chapter, by all members of the combined report shall not reduce the aggregate amount of tax, as defined in Section 23036, of all members of the combined report by more than five-million-dollars five million dollars ($5,000,000).(c) Any amounts included in an election pursuant to Section 6902.5, relating to an irrevocable election to apply credit amounts under Section 17053.85, 17053.95, 17053.98, 23685, 23695, or 23698 against qualified sales and use tax, as defined in Section 6902.5, are not included in the five million dollar five-million-dollar ($5,000,000) limitation set forth in subdivision (a) or (b).(d) The limitation under subdivision (a) or (b) shall not apply to the credit allowed by Section 23610.5 (relating to credit for low-income housing).(e) The amount of any credit otherwise allowable for the taxable year under Section 23036 that is not allowed due to the application of this section shall remain a credit carryover amount under this part.(f) The carryover period for any credit that is not allowed due to the application of this section shall be increased by the number of taxable years the credit or any portion thereof was not allowed.(g) Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code does not apply to any standard, criterion, procedure, determination, rule, notice, or guideline established or issued by the Franchise Tax Board pursuant to this section.(h) For taxable years on or after January 1, 2021, and before January 2, 2023, the five-million-dollar ($5,000,000) limitation set forth in subdivision (a) or (b) shall not apply to taxpayers that perform clinical, biomedical, or other research, development, or testing needed for COVID-19 or other diseases. research and development in biotechnology. A taxpayer performs research and development in biotechnology if the taxpayer is described in Code 325414 or 541714 of the 2017 edition of the North American Industry Classification System (NAICS) published by the United States Office of Management and Budget.
158+SEC. 4. Section 23036.3 of the Revenue and Taxation Code is amended to read:23036.3. (a) Notwithstanding any provision of this part or Part 10.2 (commencing with Section 18401) to the contrary, except as provided in subdivision (d), for taxpayers not required to be included in a combined report under Section 25101 or 25110, or taxpayers not authorized to be included in a combined report under Section 25101.15, for each taxable year beginning on or after January 1, 2020, and before January 1, 2023, the total of all credits otherwise allowable under any provision of Chapter 3.5 (commencing with Section 23604) including the carryover of any credit under a former provision of that chapter, for the taxable year shall not reduce the tax, as defined in Section 23036, by more than five million dollars ($5,000,000).(b) Notwithstanding any provision of this part or Part 10.2 (commencing with Section 18401) to the contrary, except as provided in subdivision (d), for taxpayers required to be included in a combined report under Section 25101 or 25110, or taxpayers authorized to be included in a combined report under Section 25101.15, for each taxable year beginning on or after January 1, 2020, and before January 1, 2023, the total of all credits otherwise allowable under any provision of Chapter 3.5 (commencing with Section 23604), including the carryover of any credit under a former provision of that chapter, by all members of the combined report shall not reduce the aggregate amount of tax, as defined in Section 23036, of all members of the combined report by more than five-million-dollars ($5,000,000).(c) Any amounts included in an election pursuant to Section 6902.5, relating to an irrevocable election to apply credit amounts under Section 17053.85, 17053.95, 17053.98, 23685, 23695, or 23698 against qualified sales and use tax, as defined in Section 6902.5, are not included in the five million dollar ($5,000,000) limitation set forth in subdivision (a) or (b).(d) The limitation under subdivision (a) or (b) shall not apply to the credit allowed by Section 23610.5 (relating to credit for low-income housing).(e) The amount of any credit otherwise allowable for the taxable year under Section 23036 that is not allowed due to the application of this section shall remain a credit carryover amount under this part.(f) The carryover period for any credit that is not allowed due to the application of this section shall be increased by the number of taxable years the credit or any portion thereof was not allowed.(g) Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code does not apply to any standard, criterion, procedure, determination, rule, notice, or guideline established or issued by the Franchise Tax Board pursuant to this section.(h) For taxable years on or after January 1, 2021, and before January 2, 2023, the five-million-dollar ($5,000,000) limitation set forth in subdivision (a) or (b) shall not apply to taxpayers that perform clinical, biomedical, or other research, development, or testing needed for COVID-19 or other diseases.
159159
160160 SEC. 4. Section 23036.3 of the Revenue and Taxation Code is amended to read:
161161
162162 ### SEC. 4.
163163
164-23036.3. (a) Notwithstanding any provision of this part or Part 10.2 (commencing with Section 18401) to the contrary, except as provided in subdivision (d), for taxpayers not required to be included in a combined report under Section 25101 or 25110, or taxpayers not authorized to be included in a combined report under Section 25101.15, for each taxable year beginning on or after January 1, 2020, and before January 1, 2023, the total of all credits otherwise allowable under any provision of Chapter 3.5 (commencing with Section 23604) including the carryover of any credit under a former provision of that chapter, for the taxable year shall not reduce the tax, as defined in Section 23036, by more than five million dollars ($5,000,000).(b) Notwithstanding any provision of this part or Part 10.2 (commencing with Section 18401) to the contrary, except as provided in subdivision (d), for taxpayers required to be included in a combined report under Section 25101 or 25110, or taxpayers authorized to be included in a combined report under Section 25101.15, for each taxable year beginning on or after January 1, 2020, and before January 1, 2023, the total of all credits otherwise allowable under any provision of Chapter 3.5 (commencing with Section 23604), including the carryover of any credit under a former provision of that chapter, by all members of the combined report shall not reduce the aggregate amount of tax, as defined in Section 23036, of all members of the combined report by more than five-million-dollars five million dollars ($5,000,000).(c) Any amounts included in an election pursuant to Section 6902.5, relating to an irrevocable election to apply credit amounts under Section 17053.85, 17053.95, 17053.98, 23685, 23695, or 23698 against qualified sales and use tax, as defined in Section 6902.5, are not included in the five million dollar five-million-dollar ($5,000,000) limitation set forth in subdivision (a) or (b).(d) The limitation under subdivision (a) or (b) shall not apply to the credit allowed by Section 23610.5 (relating to credit for low-income housing).(e) The amount of any credit otherwise allowable for the taxable year under Section 23036 that is not allowed due to the application of this section shall remain a credit carryover amount under this part.(f) The carryover period for any credit that is not allowed due to the application of this section shall be increased by the number of taxable years the credit or any portion thereof was not allowed.(g) Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code does not apply to any standard, criterion, procedure, determination, rule, notice, or guideline established or issued by the Franchise Tax Board pursuant to this section.(h) For taxable years on or after January 1, 2021, and before January 2, 2023, the five-million-dollar ($5,000,000) limitation set forth in subdivision (a) or (b) shall not apply to taxpayers that perform clinical, biomedical, or other research, development, or testing needed for COVID-19 or other diseases. research and development in biotechnology. A taxpayer performs research and development in biotechnology if the taxpayer is described in Code 325414 or 541714 of the 2017 edition of the North American Industry Classification System (NAICS) published by the United States Office of Management and Budget.
164+23036.3. (a) Notwithstanding any provision of this part or Part 10.2 (commencing with Section 18401) to the contrary, except as provided in subdivision (d), for taxpayers not required to be included in a combined report under Section 25101 or 25110, or taxpayers not authorized to be included in a combined report under Section 25101.15, for each taxable year beginning on or after January 1, 2020, and before January 1, 2023, the total of all credits otherwise allowable under any provision of Chapter 3.5 (commencing with Section 23604) including the carryover of any credit under a former provision of that chapter, for the taxable year shall not reduce the tax, as defined in Section 23036, by more than five million dollars ($5,000,000).(b) Notwithstanding any provision of this part or Part 10.2 (commencing with Section 18401) to the contrary, except as provided in subdivision (d), for taxpayers required to be included in a combined report under Section 25101 or 25110, or taxpayers authorized to be included in a combined report under Section 25101.15, for each taxable year beginning on or after January 1, 2020, and before January 1, 2023, the total of all credits otherwise allowable under any provision of Chapter 3.5 (commencing with Section 23604), including the carryover of any credit under a former provision of that chapter, by all members of the combined report shall not reduce the aggregate amount of tax, as defined in Section 23036, of all members of the combined report by more than five-million-dollars ($5,000,000).(c) Any amounts included in an election pursuant to Section 6902.5, relating to an irrevocable election to apply credit amounts under Section 17053.85, 17053.95, 17053.98, 23685, 23695, or 23698 against qualified sales and use tax, as defined in Section 6902.5, are not included in the five million dollar ($5,000,000) limitation set forth in subdivision (a) or (b).(d) The limitation under subdivision (a) or (b) shall not apply to the credit allowed by Section 23610.5 (relating to credit for low-income housing).(e) The amount of any credit otherwise allowable for the taxable year under Section 23036 that is not allowed due to the application of this section shall remain a credit carryover amount under this part.(f) The carryover period for any credit that is not allowed due to the application of this section shall be increased by the number of taxable years the credit or any portion thereof was not allowed.(g) Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code does not apply to any standard, criterion, procedure, determination, rule, notice, or guideline established or issued by the Franchise Tax Board pursuant to this section.(h) For taxable years on or after January 1, 2021, and before January 2, 2023, the five-million-dollar ($5,000,000) limitation set forth in subdivision (a) or (b) shall not apply to taxpayers that perform clinical, biomedical, or other research, development, or testing needed for COVID-19 or other diseases.
165165
166-23036.3. (a) Notwithstanding any provision of this part or Part 10.2 (commencing with Section 18401) to the contrary, except as provided in subdivision (d), for taxpayers not required to be included in a combined report under Section 25101 or 25110, or taxpayers not authorized to be included in a combined report under Section 25101.15, for each taxable year beginning on or after January 1, 2020, and before January 1, 2023, the total of all credits otherwise allowable under any provision of Chapter 3.5 (commencing with Section 23604) including the carryover of any credit under a former provision of that chapter, for the taxable year shall not reduce the tax, as defined in Section 23036, by more than five million dollars ($5,000,000).(b) Notwithstanding any provision of this part or Part 10.2 (commencing with Section 18401) to the contrary, except as provided in subdivision (d), for taxpayers required to be included in a combined report under Section 25101 or 25110, or taxpayers authorized to be included in a combined report under Section 25101.15, for each taxable year beginning on or after January 1, 2020, and before January 1, 2023, the total of all credits otherwise allowable under any provision of Chapter 3.5 (commencing with Section 23604), including the carryover of any credit under a former provision of that chapter, by all members of the combined report shall not reduce the aggregate amount of tax, as defined in Section 23036, of all members of the combined report by more than five-million-dollars five million dollars ($5,000,000).(c) Any amounts included in an election pursuant to Section 6902.5, relating to an irrevocable election to apply credit amounts under Section 17053.85, 17053.95, 17053.98, 23685, 23695, or 23698 against qualified sales and use tax, as defined in Section 6902.5, are not included in the five million dollar five-million-dollar ($5,000,000) limitation set forth in subdivision (a) or (b).(d) The limitation under subdivision (a) or (b) shall not apply to the credit allowed by Section 23610.5 (relating to credit for low-income housing).(e) The amount of any credit otherwise allowable for the taxable year under Section 23036 that is not allowed due to the application of this section shall remain a credit carryover amount under this part.(f) The carryover period for any credit that is not allowed due to the application of this section shall be increased by the number of taxable years the credit or any portion thereof was not allowed.(g) Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code does not apply to any standard, criterion, procedure, determination, rule, notice, or guideline established or issued by the Franchise Tax Board pursuant to this section.(h) For taxable years on or after January 1, 2021, and before January 2, 2023, the five-million-dollar ($5,000,000) limitation set forth in subdivision (a) or (b) shall not apply to taxpayers that perform clinical, biomedical, or other research, development, or testing needed for COVID-19 or other diseases. research and development in biotechnology. A taxpayer performs research and development in biotechnology if the taxpayer is described in Code 325414 or 541714 of the 2017 edition of the North American Industry Classification System (NAICS) published by the United States Office of Management and Budget.
166+23036.3. (a) Notwithstanding any provision of this part or Part 10.2 (commencing with Section 18401) to the contrary, except as provided in subdivision (d), for taxpayers not required to be included in a combined report under Section 25101 or 25110, or taxpayers not authorized to be included in a combined report under Section 25101.15, for each taxable year beginning on or after January 1, 2020, and before January 1, 2023, the total of all credits otherwise allowable under any provision of Chapter 3.5 (commencing with Section 23604) including the carryover of any credit under a former provision of that chapter, for the taxable year shall not reduce the tax, as defined in Section 23036, by more than five million dollars ($5,000,000).(b) Notwithstanding any provision of this part or Part 10.2 (commencing with Section 18401) to the contrary, except as provided in subdivision (d), for taxpayers required to be included in a combined report under Section 25101 or 25110, or taxpayers authorized to be included in a combined report under Section 25101.15, for each taxable year beginning on or after January 1, 2020, and before January 1, 2023, the total of all credits otherwise allowable under any provision of Chapter 3.5 (commencing with Section 23604), including the carryover of any credit under a former provision of that chapter, by all members of the combined report shall not reduce the aggregate amount of tax, as defined in Section 23036, of all members of the combined report by more than five-million-dollars ($5,000,000).(c) Any amounts included in an election pursuant to Section 6902.5, relating to an irrevocable election to apply credit amounts under Section 17053.85, 17053.95, 17053.98, 23685, 23695, or 23698 against qualified sales and use tax, as defined in Section 6902.5, are not included in the five million dollar ($5,000,000) limitation set forth in subdivision (a) or (b).(d) The limitation under subdivision (a) or (b) shall not apply to the credit allowed by Section 23610.5 (relating to credit for low-income housing).(e) The amount of any credit otherwise allowable for the taxable year under Section 23036 that is not allowed due to the application of this section shall remain a credit carryover amount under this part.(f) The carryover period for any credit that is not allowed due to the application of this section shall be increased by the number of taxable years the credit or any portion thereof was not allowed.(g) Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code does not apply to any standard, criterion, procedure, determination, rule, notice, or guideline established or issued by the Franchise Tax Board pursuant to this section.(h) For taxable years on or after January 1, 2021, and before January 2, 2023, the five-million-dollar ($5,000,000) limitation set forth in subdivision (a) or (b) shall not apply to taxpayers that perform clinical, biomedical, or other research, development, or testing needed for COVID-19 or other diseases.
167167
168-23036.3. (a) Notwithstanding any provision of this part or Part 10.2 (commencing with Section 18401) to the contrary, except as provided in subdivision (d), for taxpayers not required to be included in a combined report under Section 25101 or 25110, or taxpayers not authorized to be included in a combined report under Section 25101.15, for each taxable year beginning on or after January 1, 2020, and before January 1, 2023, the total of all credits otherwise allowable under any provision of Chapter 3.5 (commencing with Section 23604) including the carryover of any credit under a former provision of that chapter, for the taxable year shall not reduce the tax, as defined in Section 23036, by more than five million dollars ($5,000,000).(b) Notwithstanding any provision of this part or Part 10.2 (commencing with Section 18401) to the contrary, except as provided in subdivision (d), for taxpayers required to be included in a combined report under Section 25101 or 25110, or taxpayers authorized to be included in a combined report under Section 25101.15, for each taxable year beginning on or after January 1, 2020, and before January 1, 2023, the total of all credits otherwise allowable under any provision of Chapter 3.5 (commencing with Section 23604), including the carryover of any credit under a former provision of that chapter, by all members of the combined report shall not reduce the aggregate amount of tax, as defined in Section 23036, of all members of the combined report by more than five-million-dollars five million dollars ($5,000,000).(c) Any amounts included in an election pursuant to Section 6902.5, relating to an irrevocable election to apply credit amounts under Section 17053.85, 17053.95, 17053.98, 23685, 23695, or 23698 against qualified sales and use tax, as defined in Section 6902.5, are not included in the five million dollar five-million-dollar ($5,000,000) limitation set forth in subdivision (a) or (b).(d) The limitation under subdivision (a) or (b) shall not apply to the credit allowed by Section 23610.5 (relating to credit for low-income housing).(e) The amount of any credit otherwise allowable for the taxable year under Section 23036 that is not allowed due to the application of this section shall remain a credit carryover amount under this part.(f) The carryover period for any credit that is not allowed due to the application of this section shall be increased by the number of taxable years the credit or any portion thereof was not allowed.(g) Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code does not apply to any standard, criterion, procedure, determination, rule, notice, or guideline established or issued by the Franchise Tax Board pursuant to this section.(h) For taxable years on or after January 1, 2021, and before January 2, 2023, the five-million-dollar ($5,000,000) limitation set forth in subdivision (a) or (b) shall not apply to taxpayers that perform clinical, biomedical, or other research, development, or testing needed for COVID-19 or other diseases. research and development in biotechnology. A taxpayer performs research and development in biotechnology if the taxpayer is described in Code 325414 or 541714 of the 2017 edition of the North American Industry Classification System (NAICS) published by the United States Office of Management and Budget.
168+23036.3. (a) Notwithstanding any provision of this part or Part 10.2 (commencing with Section 18401) to the contrary, except as provided in subdivision (d), for taxpayers not required to be included in a combined report under Section 25101 or 25110, or taxpayers not authorized to be included in a combined report under Section 25101.15, for each taxable year beginning on or after January 1, 2020, and before January 1, 2023, the total of all credits otherwise allowable under any provision of Chapter 3.5 (commencing with Section 23604) including the carryover of any credit under a former provision of that chapter, for the taxable year shall not reduce the tax, as defined in Section 23036, by more than five million dollars ($5,000,000).(b) Notwithstanding any provision of this part or Part 10.2 (commencing with Section 18401) to the contrary, except as provided in subdivision (d), for taxpayers required to be included in a combined report under Section 25101 or 25110, or taxpayers authorized to be included in a combined report under Section 25101.15, for each taxable year beginning on or after January 1, 2020, and before January 1, 2023, the total of all credits otherwise allowable under any provision of Chapter 3.5 (commencing with Section 23604), including the carryover of any credit under a former provision of that chapter, by all members of the combined report shall not reduce the aggregate amount of tax, as defined in Section 23036, of all members of the combined report by more than five-million-dollars ($5,000,000).(c) Any amounts included in an election pursuant to Section 6902.5, relating to an irrevocable election to apply credit amounts under Section 17053.85, 17053.95, 17053.98, 23685, 23695, or 23698 against qualified sales and use tax, as defined in Section 6902.5, are not included in the five million dollar ($5,000,000) limitation set forth in subdivision (a) or (b).(d) The limitation under subdivision (a) or (b) shall not apply to the credit allowed by Section 23610.5 (relating to credit for low-income housing).(e) The amount of any credit otherwise allowable for the taxable year under Section 23036 that is not allowed due to the application of this section shall remain a credit carryover amount under this part.(f) The carryover period for any credit that is not allowed due to the application of this section shall be increased by the number of taxable years the credit or any portion thereof was not allowed.(g) Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code does not apply to any standard, criterion, procedure, determination, rule, notice, or guideline established or issued by the Franchise Tax Board pursuant to this section.(h) For taxable years on or after January 1, 2021, and before January 2, 2023, the five-million-dollar ($5,000,000) limitation set forth in subdivision (a) or (b) shall not apply to taxpayers that perform clinical, biomedical, or other research, development, or testing needed for COVID-19 or other diseases.
169169
170170
171171
172172 23036.3. (a) Notwithstanding any provision of this part or Part 10.2 (commencing with Section 18401) to the contrary, except as provided in subdivision (d), for taxpayers not required to be included in a combined report under Section 25101 or 25110, or taxpayers not authorized to be included in a combined report under Section 25101.15, for each taxable year beginning on or after January 1, 2020, and before January 1, 2023, the total of all credits otherwise allowable under any provision of Chapter 3.5 (commencing with Section 23604) including the carryover of any credit under a former provision of that chapter, for the taxable year shall not reduce the tax, as defined in Section 23036, by more than five million dollars ($5,000,000).
173173
174-(b) Notwithstanding any provision of this part or Part 10.2 (commencing with Section 18401) to the contrary, except as provided in subdivision (d), for taxpayers required to be included in a combined report under Section 25101 or 25110, or taxpayers authorized to be included in a combined report under Section 25101.15, for each taxable year beginning on or after January 1, 2020, and before January 1, 2023, the total of all credits otherwise allowable under any provision of Chapter 3.5 (commencing with Section 23604), including the carryover of any credit under a former provision of that chapter, by all members of the combined report shall not reduce the aggregate amount of tax, as defined in Section 23036, of all members of the combined report by more than five-million-dollars five million dollars ($5,000,000).
174+(b) Notwithstanding any provision of this part or Part 10.2 (commencing with Section 18401) to the contrary, except as provided in subdivision (d), for taxpayers required to be included in a combined report under Section 25101 or 25110, or taxpayers authorized to be included in a combined report under Section 25101.15, for each taxable year beginning on or after January 1, 2020, and before January 1, 2023, the total of all credits otherwise allowable under any provision of Chapter 3.5 (commencing with Section 23604), including the carryover of any credit under a former provision of that chapter, by all members of the combined report shall not reduce the aggregate amount of tax, as defined in Section 23036, of all members of the combined report by more than five-million-dollars ($5,000,000).
175175
176-(c) Any amounts included in an election pursuant to Section 6902.5, relating to an irrevocable election to apply credit amounts under Section 17053.85, 17053.95, 17053.98, 23685, 23695, or 23698 against qualified sales and use tax, as defined in Section 6902.5, are not included in the five million dollar five-million-dollar ($5,000,000) limitation set forth in subdivision (a) or (b).
176+(c) Any amounts included in an election pursuant to Section 6902.5, relating to an irrevocable election to apply credit amounts under Section 17053.85, 17053.95, 17053.98, 23685, 23695, or 23698 against qualified sales and use tax, as defined in Section 6902.5, are not included in the five million dollar ($5,000,000) limitation set forth in subdivision (a) or (b).
177177
178178 (d) The limitation under subdivision (a) or (b) shall not apply to the credit allowed by Section 23610.5 (relating to credit for low-income housing).
179179
180180 (e) The amount of any credit otherwise allowable for the taxable year under Section 23036 that is not allowed due to the application of this section shall remain a credit carryover amount under this part.
181181
182182 (f) The carryover period for any credit that is not allowed due to the application of this section shall be increased by the number of taxable years the credit or any portion thereof was not allowed.
183183
184184 (g) Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code does not apply to any standard, criterion, procedure, determination, rule, notice, or guideline established or issued by the Franchise Tax Board pursuant to this section.
185185
186-(h) For taxable years on or after January 1, 2021, and before January 2, 2023, the five-million-dollar ($5,000,000) limitation set forth in subdivision (a) or (b) shall not apply to taxpayers that perform clinical, biomedical, or other research, development, or testing needed for COVID-19 or other diseases. research and development in biotechnology. A taxpayer performs research and development in biotechnology if the taxpayer is described in Code 325414 or 541714 of the 2017 edition of the North American Industry Classification System (NAICS) published by the United States Office of Management and Budget.
186+(h) For taxable years on or after January 1, 2021, and before January 2, 2023, the five-million-dollar ($5,000,000) limitation set forth in subdivision (a) or (b) shall not apply to taxpayers that perform clinical, biomedical, or other research, development, or testing needed for COVID-19 or other diseases.
187187
188188 SEC. 5. (a) For purposes of Section 41 of the Revenue and Taxation Code, with respect to the tax expenditure created by the amendments to Sections 17039.3, 17276.23, and 23036.3 of the Revenue and Taxation Code made by this act, the Legislature finds and declares the following:(1) The specific goals, purposes, and objectives of this bill are as follows:(A) To encourage the activity of life sciences research in California.(B) To incentivize more research into treatments, cures, and vaccines to address the global pandemic caused by COVID-19.(2) To measure whether the credit achieves its intended purpose, the Franchise Tax Board shall prepare a written report on all of the following:(A) The number of taxpayers claiming the credit.(B) The average credit amount on tax returns claiming the credit.(C) Where applicable the type of taxpayer claiming the credit.(b) Notwithstanding Section 19542 of the Revenue and Taxation Code, the Franchise Tax Board shall provide the written report prepared pursuant to paragraph (2) of subdivision (a) to the Senate Committee on Budget and Fiscal Review, the Assembly Committee on Budget, the Senate and Assembly Committees on Appropriations, the Senate Committee on Governance and Finance, and the Assembly Committee on Revenue and Taxation. The report shall be submitted in compliance with Section 9795 of the Government Code.
189189
190190 SEC. 5. (a) For purposes of Section 41 of the Revenue and Taxation Code, with respect to the tax expenditure created by the amendments to Sections 17039.3, 17276.23, and 23036.3 of the Revenue and Taxation Code made by this act, the Legislature finds and declares the following:(1) The specific goals, purposes, and objectives of this bill are as follows:(A) To encourage the activity of life sciences research in California.(B) To incentivize more research into treatments, cures, and vaccines to address the global pandemic caused by COVID-19.(2) To measure whether the credit achieves its intended purpose, the Franchise Tax Board shall prepare a written report on all of the following:(A) The number of taxpayers claiming the credit.(B) The average credit amount on tax returns claiming the credit.(C) Where applicable the type of taxpayer claiming the credit.(b) Notwithstanding Section 19542 of the Revenue and Taxation Code, the Franchise Tax Board shall provide the written report prepared pursuant to paragraph (2) of subdivision (a) to the Senate Committee on Budget and Fiscal Review, the Assembly Committee on Budget, the Senate and Assembly Committees on Appropriations, the Senate Committee on Governance and Finance, and the Assembly Committee on Revenue and Taxation. The report shall be submitted in compliance with Section 9795 of the Government Code.
191191
192192 SEC. 5. (a) For purposes of Section 41 of the Revenue and Taxation Code, with respect to the tax expenditure created by the amendments to Sections 17039.3, 17276.23, and 23036.3 of the Revenue and Taxation Code made by this act, the Legislature finds and declares the following:
193193
194194 ### SEC. 5.
195195
196196 (1) The specific goals, purposes, and objectives of this bill are as follows:
197197
198198 (A) To encourage the activity of life sciences research in California.
199199
200200 (B) To incentivize more research into treatments, cures, and vaccines to address the global pandemic caused by COVID-19.
201201
202202 (2) To measure whether the credit achieves its intended purpose, the Franchise Tax Board shall prepare a written report on all of the following:
203203
204204 (A) The number of taxpayers claiming the credit.
205205
206206 (B) The average credit amount on tax returns claiming the credit.
207207
208208 (C) Where applicable the type of taxpayer claiming the credit.
209209
210210 (b) Notwithstanding Section 19542 of the Revenue and Taxation Code, the Franchise Tax Board shall provide the written report prepared pursuant to paragraph (2) of subdivision (a) to the Senate Committee on Budget and Fiscal Review, the Assembly Committee on Budget, the Senate and Assembly Committees on Appropriations, the Senate Committee on Governance and Finance, and the Assembly Committee on Revenue and Taxation. The report shall be submitted in compliance with Section 9795 of the Government Code.
211211
212212 SEC. 6. This act provides for a tax levy within the meaning of Article IV of the California Constitution and shall go into immediate effect.
213213
214214 SEC. 6. This act provides for a tax levy within the meaning of Article IV of the California Constitution and shall go into immediate effect.
215215
216216 SEC. 6. This act provides for a tax levy within the meaning of Article IV of the California Constitution and shall go into immediate effect.
217217
218218 ### SEC. 6.